

1 **Enhanced metanephric specification to functional proximal tubule enables toxicity**
2 **screening and infectious disease modelling in kidney organoids**

3

4 Jessica M. Vanslambrouck^{1,2}, Sean B. Wilson^{1,2#}, Ker Sin Tan^{1#}, Ella Groenewegen¹, Rajeev
5 Rudraraju⁴, Jessica Neil⁴, Michelle Scurr¹, Sara E. Howden^{1,2}, Kanta Subbarao⁴, Melissa H.
6 Little^{1,2,3*}.

7

8 1. Murdoch Children's Research Institute, Flemington Rd, Parkville, VIC, Australia

9 2. Department of Paediatrics, The University of Melbourne, VIC, Australia.

10 3. Department of Anatomy and Neuroscience, The University of Melbourne, VIC, Australia.

11 4. Department of Microbiology and Immunology, The Peter Doherty Institute for Infection
12 and Immunity, The University of Melbourne, VIC, Australia.

13 # Equal contribution

14 * Author for correspondence:

15 M.H.L.: +61 3 9936 6206; melissa.little@mcri.edu.au

16

17 Running title: Enhanced proximal tubules

18 Keywords: proximal tubule, pluripotent stem cell, kidney organoid, nephron patterning

19

20

21 **Abstract**

22 While pluripotent stem cell-derived kidney organoids represent a promising approach for the
23 study of renal disease, renal physiology and drug screening, the proximal nephron remains
24 immature with limited evidence for key functional solute channels. This may reflect early
25 mispatterning of the nephrogenic mesenchyme or insufficient maturation. In this study,
26 prolonged differentiation and modification of media conditions to enhance metanephric
27 nephron progenitor specification resulted in the induction of nephrons containing elongated
28 and aligned proximal nephron segments together with SLC12A1⁺ loops of Henle. Nephron
29 proximal segments showed superior *HNF4A* gene and protein expression, as well as
30 upregulation of key functional transporters, including *SLC3A1/2*, *SLC47A1*, and *SLC22A2*. The
31 striking proximo-distal orientation of nephrons was shown to result from localised WNT
32 antagonism originating from the centre of the organoid. Functionality of such transporters was
33 evidenced by albumin and organic cation uptake, as well as appropriate KIM-1 upregulation in
34 response to the nephrotoxicant, cisplatin. PT-enhanced organoids also possessed improved
35 expression of receptors associated with SARS-CoV2 entry, rendering these organoids
36 susceptible to infection and able to support viral replication without co-location of ACE2 and
37 TMPRSS2. These PT-enhanced organoids provide an accurate model with which to study
38 human proximal tubule maturation, inherited and acquired proximal tubular disease, and drug
39 and viral responses.

40

41 **Introduction**

42 Chronic kidney disease (CKD) is an increasing global health and economic burden, attributed
43 to 1.2 million deaths worldwide in 2017 alone (Collaboration, 2020). Most commonly associated
44 with diabetes and high blood pressure, CKD also arises from genetic disorders, infections, and
45 drug-induced toxicity. Key cellular targets of this disease are the kidney proximal tubules
46 which possess a high metabolic activity making them acutely vulnerable to toxins and
47 metabolic stress (Kiritu, *et al.*, 2020). In mammals, this highly specialised segment of the
48 nephron performs the bulk of kidney reabsorption and secretion via three distinct functional
49 and anatomical segments: the convoluted (S1 and S2) proximal tubule segments and the
50 straight (S3) segment that traverses the cortico-medullary boundary. Of these, S1 exhibits the
51 highest capacity for solute, sodium, amino acid and fluid transport (Zhuo and Li, 2013). The
52 dramatic effect that proximal tubule injury has on body homeostasis underpins the complexities
53 faced in CKD management. While current CKD treatment options such as dialysis and
54 transplantation can be life-prolonging, they are complicated by high morbidity rates and donor
55 organ shortages (Collaboration, 2020). These treatment deficits are further confounded by our
56 limited understanding of disease mechanisms due to a lack of accurate human-relevant disease
57 models.

58 We and others have established robust protocols for the directed differentiation of human
59 pluripotent stem cells to kidney progenitors capable of self-organisation into complex kidney
60 structures (Freedman, *et al.*, 2015; Morizane, *et al.*, 2015; Taguchi, *et al.*, 2014; Toyohara, *et*
61 *al.*, 2015). These kidney organoids show a remarkable transcriptional similarity to the
62 developing human kidney (Combes, *et al.*, 2019; Howden, *et al.*, 2021; Subramanian, *et al.*,
63 2019; Wu, *et al.*, 2018), most closely resembling human trimester 1 development by 3-4 weeks
64 of culture (Takasato, *et al.*, 2015) and possessing many of the structures expected within fetal
65 kidney *in vivo*, including glomeruli, nephrons, stroma and vasculature (Takasato, *et al.*, 2016).
66 However, nephron patterning and segmentation remain noticeably immature in kidney
67 organoids, even in comparison to the fetal organ. This is particularly noticeable in the proximal
68 tubule segment of the nephron. While there is clear expression of *HNF4A*, responsible for
69 driving early proximal patterning (Marable, *et al.*, 2020), and characteristic apical co-
70 localisation of the CUBILIN-MEGALIN complex, existing kidney organoid protocols fail to
71 promote the expression and maturation of the functional solute channels that define each
72 proximal tubule subsegment (Wu, *et al.*, 2018; Wilson, *et al.*, 2021). Critically, expression

73 levels of the principal water transporting channel, AQP1, the organic anion transporters
74 (OATs), and the organic anion transporters (OATs) are all low (Wilson, *et al.*, 2021) This
75 represents a considerable obstacle to the modelling of proximal tubular disorders or the
76 screening of drugs or toxins using kidney organoids.

77 Suboptimal proximal tubule maturation in organoids may be regarded as a problem of
78 inappropriate anteroposterior/mediolateral patterning, suboptimal maintenance of progenitor
79 identity or incomplete maturation. In response to distinct temporospatial signalling, the
80 permanent (metanephric) kidney arises during human embryogenesis as the final of three
81 embryonic excretory organs, developing sequentially from specific rostrocaudal regions of the
82 intermediate mesoderm located between the lateral plate mesoderm and paraxial somatic
83 mesoderm (Dressler, 2009). Metanephric kidney development in humans commences during
84 weeks 4 – 5 (de Bakker, *et al.*, 2019) with the first nephrons appearing by week 6 – 7. In mouse
85 and human, nephron formation involves a mesenchyme to epithelial transition (MET) from a
86 population of SIX2⁺ nephron progenitors that form a cap mesenchyme around the tips of the
87 branching collecting duct (Kobayashi, *et al.*, 2008; Lindstrom, *et al.*, 2018). However,
88 preceding metanephric development is the formation of two more rostral transient excretory
89 organs; the pronephros (present in human from gestation week 3 - 4) and the mesonephros
90 (present in human from gestation week 4 – 10). While the mammalian pronephros is highly
91 rudimentary, mesonephric nephrons also arise via MET and show similar patterning and
92 segmentation to metanephric nephrons, albeit with less definitive distal tubule segments
93 (Georgas, *et al.*, 2011; Mugford, *et al.*, 2008; Tiedemann, *et al.*, 1987). The mesonephros
94 functions as the principle excretory organ until week 8 after which time it regresses suggesting
95 that mesonephric tubular function is less advanced compared to the metanephros (reviewed in
96 de Bakker, *et al.*, 2019).

97 Using fluorescent reporter lines and lineage tracing in human kidney organoids, we have
98 confirmed both the presence of a SIX2⁺ nephron progenitor population and the contribution of
99 these cells to nephrogenesis via MET in kidney organoids (Howden, *et al.*, 2019;
100 Vanslambrouck, *et al.*, 2019). However, given the short duration of ours and other organoid
101 protocols (reviewed in Little and Combes, 2019), the possibility exists that we are modelling
102 mesonephric rather than metanephric nephrogenesis, potentially contributing to poor proximal
103 tubule patterning and maturation. In agreement with this notion, previous studies have observed
104 variations in anteroposterior patterning of the intermediate mesoderm during hPSC

105 differentiation *in vitro* (Taguchi, *et al.*, 2014; Takasato, *et al.*, 2015; Tsujimoto, *et al.*, 2020).
106 The influence of mediolateral signalling cues during mesodermal patterning further complicate
107 iPSC differentiation, with inappropriate signalling likely to influence paraxial or lateral plate
108 mesoderm proportion, thus reducing effective nephron generation.

109 An alternate contributing factor is suboptimal maintenance of progenitor identity during iPSC
110 differentiation and organoid generation. Several media have been described that are able to
111 support the maintenance of isolated nephron progenitors *in vitro* (Brown, *et al.*, 2015; Li, *et*
112 *al.*, 2016; Tanigawa, *et al.*, 2015; Tanigawa, *et al.*, 2016). While each media contains low levels
113 of canonical WNT activity and FGF2/9, the inclusion of a variety of TGF β superfamily
114 agonists (BMP4, BMP7, Activin A) and antagonists (A83-01, LDN193189), NOTCH
115 inhibition (DAPT), and other growth factors (TGF α , IGF1/2, LIF) varies between media. These
116 media have been referred to as NPEM, NPSR, and CDBLY based upon their components, with
117 all studies reporting maintenance of a SIX2-expressing nephron progenitor population in
118 culture across time (Brown, *et al.*, 2015; Li, *et al.*, 2016; Tanigawa, *et al.*, 2016). However, the
119 resulting nephrons formed after subsequent nephron induction showed distinct differences in
120 nephron patterning. In NPEM, the inclusion of LDN193189 (inhibitor of BMP receptor-
121 mediated SMAD1/5/8) supported tubular patterning but not formation of glomeruli (Brown, *et*
122 *al.*, 2015). In contrast, the addition of LIF and either dual-SMAD inhibition (LDN193189 and
123 A83-01) or NOTCH inhibition (DAPT) resulted in the formation of nephrons with podocytes
124 but distinct nephron morphologies (Li, *et al.*, 2016; Tanigawa, *et al.*, 2016). While
125 proximodistal nephron patterning in mouse has previously been shown to be influenced by
126 relative Wnt, Bmp, and Notch signalling in mouse (Lindstrom, *et al.*, 2015), these data suggest
127 that distinct nephron progenitor states may show varying competence for different nephron
128 segments, or that distinct SIX2 populations give rise to different regions of the nephron.

129 In the current study, we sought to understand whether anteroposterior/mediolateral patterning,
130 or shifts in commitment state of the nephron progenitors, could influence ultimate proximal
131 tubule identity and maturation. We initially sought to maximise patterning to a posterior
132 metanephric SIX2⁺ nephron progenitor population by extending the duration of mesodermal
133 patterning, simultaneously suppressing MET and supporting nephron progenitor expansion
134 using previously described media (Li, *et al.*, 2016; Tanigawa, *et al.*, 2016). Compared to
135 standard pluripotent stem cell-derived kidney organoids, prolonged monolayer iPSC
136 differentiation in modified CDBLY nephron progenitor maintenance media (Tanigawa, *et al.*,

137 2016) specified nephron progenitors with improved metanephric identity without influencing
138 anteroposterior/mediolateral patterning. These progenitors formed strongly proximalised,
139 elongated, and spatially aligned nephrons, with striking proximo-distal nephron orientation
140 resulting from localised WNT antagonism. Proximal tubules possessed substantially improved
141 maturation, evidenced by upregulation of key solute channels and transporters. This was
142 strengthened by their functional uptake of albumin, organic cations, and cisplatin, eliciting
143 appropriate KIM-1 upregulation. Improved proximal tubules of these enhanced organoids also
144 showed increased expression of key viral entry factors for SARS-CoV-2 compared to previous
145 protocols, validating the proximal tubule as the primary target for viral entry despite a complete
146 separation of the viral receptor, ACE2 (proximal tubule), and the viral entry cofactor,
147 TMPRSS2 (distal tubule). Taken together, this study suggests a requirement for optimal
148 nephron progenitor commitment for appropriate proximal tubule identity. Proximal tubule-
149 enhanced kidney organoids represent an improved model of the human nephron with likely
150 applications for infectious and genetic disease research, as well as evaluation of drug responses.

151

152

153 **Results**

154 **Prolonged monolayer culture and delayed nephron induction supports nephron**
155 **progenitors**

156 As noted previously, optimisation of nephron progenitor maintenance *in vitro* has been
157 investigated by a range of studies using murine and human pluripotent stem cell-derived
158 nephron progenitors (Brown, *et al.*, 2015; Li, *et al.*, 2016; Tanigawa, *et al.*, 2016). While all
159 studies reported maintenance of nephron progenitors, variations were evident with respect to
160 the final patterning of resulting nephrons following induction. Given the clear influence that
161 initial differentiation conditions and timing can have on nephron progenitor survival and
162 subsequent nephron patterning, we hypothesised that expanding our nephron progenitor
163 population whilst delaying nephron initiation may create a more metanephric population
164 leading to organoids with improved patterning and PT maturation. We have previously shown
165 that SIX2 expression is not detected until day 10 of pluripotent stem cell differentiation
166 (Howden, *et al.*, 2019). Hence, the initial monolayer differentiation phase was prolonged to
167 between 12 – 14 days, along with culture in either of two previously defined NP maintenance
168 media, NPSR (Li, *et al.*, 2016) and CDBLY (Tanigawa, *et al.*, 2016) from day 7, which
169 represents the point of intermediate mesoderm commitment (Takasato, *et al.*, 2015; Takasato,
170 *et al.*, 2014) (Figure 1A). Compared to control media (TeSR-E6; E6), both NPSR and CDBLY
171 prevented spontaneous epithelialisation of the monolayer (Figure 1B). However, only CDBLY
172 preserved the nephron-forming capacity of the progenitor cells following micromass formation
173 and induction of nephrogenesis with a pulse of canonical WNT signalling (Figure 1B). By
174 contrast, very little epithelialisation and poor nephron commitment was observed after culture
175 in NPSR (Figure 1B).

176 The prevention of spontaneous differentiation while preserving the nephrogenic capacity of the
177 NP cells was found to be primarily a response to the presence of CDB (CHIR, DAPT, BMP7),
178 with omission of LIF, Y27632, as well as the basal media component TGF α , found to produce
179 a similar result with respect to growth, morphology and nephron segmentation compared to
180 CDBLY (Figure 1C). The inhibition of monolayer epithelialisation with preserved nephrogenic
181 capacity was found to be consistent at monolayer differentiation lengths tested (10, 12, 13 and
182 14 days) (Supplementary Fig 1A). However, a monolayer differentiation length of 12 – 13 days
183 produced more consistent nephrogenesis between experiments, with 14 days leading to

184 frequent detachment of the differentiating monolayer. Subsequent studies proceeded using
185 prolonged culture in CDBLY noting the inclusion of an increased concentration of BMP7
186 (10ng/mL; CDBLY2) which improved reproducibility of organoid nephrogenesis between
187 organoids compared to standard CDBLY (5ng/mL BMP7) (Supplementary Figure 1B). This
188 modified differentiation protocol is detailed in Figure 1A.

189 Quantitative RT-PCR (qRT-PCR) of the extended monolayer differentiations in CDBLY2
190 confirmed an improved metanephric gene expression profile compared to standard
191 differentiations performed in parallel (7 day protocol in E6 (Takasato, *et al.*, 2016; Howden, *et*
192 *al.*, 2019)) (Figure 1D). Extended CDBLY2 monolayers showed a significant increase in
193 *SIX1/SIX2* (self-renewing to committed NPs) and *WNT4* (primed to committed NPs), while
194 *DAPL1* (self-renewing and primed NPs) was increased without significance and no change was
195 observed in *TMEM100* (self-renewing NPs). This suggested that the extended protocol
196 promotes a primed, rather than self-renewing, NPC population (Hochane, *et al.*, 2019;
197 Lindstrom, *et al.*, 2018; Lindstrom, *et al.*, 2018). Extended differentiation in CDBLY2 was not
198 found to alter mediolateral patterning, with no change in paraxial mesodermal marker
199 *PARAXIS* and unchanged or increased expression of intermediate mesoderm markers
200 *HOXD11*, *LHX1*, and *GATA3* (Mugford, *et al.*, 2008).

201 **Extended monolayer culture induces SIX2-derived proximalised nephrons**

202 Lineage tracing studies in mouse have shown that nephrons are derived entirely from Six2+
203 nephron progenitors (Kobayashi, *et al.*, 2008), with histological studies suggesting a similar
204 developmental process in human (Lindstrom, *et al.*, 2018; Lindstrom, *et al.*, 2018) (
205 (Kobayashi, *et al.*, 2008). Using a *SIX2*^{Cre/Cre}:GAPDH^{dual} lineage tracing line, in which SIX2
206 expression induces a permanent GFP/mCherry switch, we have previously shown that kidney
207 organoid nephrons contain cells derived from SIX2⁺, at also SIX2⁻, progenitor cells, resulting
208 in a chimeric appearance (Howden, *et al.*, 2019). To confirm and compare the competence of
209 the metanephric progenitor-enriched monolayer differentiation to contribute to nephron
210 formation, organoids were generated from our extended and the standard differentiation
211 protocol using the *SIX2*^{Cre/Cre}:GAPDH^{dual} lineage tracing line. Immunofluorescence of
212 extended protocol organoids confirmed an increase in the contribution of SIX2-derived cells
213 within the forming nephrons, including NPHS1⁺ podocytes, LTL⁺ proximal tubules and E-
214 CADHERIN⁺ distal tubules (Figure 2A). Using flow cytometry, SIX2-derived cell contribution

215 to EPCAM⁺ nephrons was significantly higher in organoids derived from the metanephric
216 progenitor-enriched monolayers compared to standard organoids, suggesting improved
217 metanephric identity of prolonged monolayers exposed to CDBLY2 (Figure 2B).

218 The patterning of these increasingly SIX2-progenitor nephrons was examined using a range of
219 markers for podocytes, proximal, and distal tubules, indicating clear proximo-distal
220 segmentation and a large proportion of proximal tubule (Figure 2C), with little to no GATA3
221 expression marking ureteric epithelialisation (Figure 2D). Organoids also displayed aligned
222 nephrons, with a central ring of glomeruli and elongated proximal tubules radiating outwards.
223 This unique organoid morphology was observed in organoids derived from 6 different iPSC
224 lines with or without gene editing and from male or female iPSC sources (3 examples
225 evidenced in Supplementary Figure 1C). The proportion of proximal tubule cells in organoids
226 derived from extended monolayer culture with CDBLY2 was compared to those derived from
227 the standard differentiation protocol (7 days differentiation, cultured in E6 (Howden, *et al.*,
228 2019)). Organoids were generated using the HNF4A^{YFP} iPSC reporter line which reports the
229 formation of proximal tubule (Vanslambrouck, *et al.*, 2019). This revealed up to 6.2 times
230 higher average proportions of HNF4A^{YFP+} proximal tubule cells in organoids derived from the
231 extended monolayer protocol compared to the standard protocol (Figure 2D). These results
232 confirmed the use of extended monolayer differentiation combined with progenitor-supportive
233 media, CDBLY2, as an effective method of generating proximal tubule enhanced (PT-
234 enhanced) kidney organoids.

235 **Transcriptional profiling of PT-enhanced organoids confirms improved proximal tubule** 236 **patterning and maturation**

237 To gain deeper insight into the complexity and maturity of cells within this extended protocol,
238 both as the stage of monolayer (day 13) and within the resulting PT-enhanced organoids,
239 transcriptional profiling was performed using multiplexed single cell RNA sequencing
240 (scRNAseq) and antibody-based cell barcoding. To account for variation, libraries were
241 generated from 4 separate differentiated monolayers representing distinct starting pools of
242 iPSCs (CRL1502.C32) that were used to generate 4 separate batches of organoids (Figure 3A).
243 Cells from the 4 replicates (both at day 13 [D13] monolayer stage, prior to organoid formation,
244 and day 14 of organoid culture [D13+14]) were barcoded using hashing antibodies before being

245 pooled. This approach produced a single library for each timepoint (sample) which could be
246 later deconvoluted to retrieve replicate information.

247 The resulting D13 and D13+14 pooled replicate libraries resolved 19,956 and 15,852 individual
248 cell transcriptomes per timepoint, respectively. UMAP plots showed the resolution of distinct
249 clusters for both D13 monolayers and resulting PT-enhanced (D13+14) organoids (Figure 3B).
250 Gene expression analyses confirmed the expression of a range of markers for mesenchymal
251 cell states pre-kidney organogenesis in D13 monolayers, as well as markers of proximodistal
252 patterning, stroma, and endothelium in D13+14 organoids (Supplementary Figure 2;
253 Supplementary Tables 1 and 2). To enable unbiased comparisons of kidney cell type
254 proportions and gene expression levels of D13 and D13+14 samples with published stem cell-
255 derived and reference kidney datasets, datasets were analysed using *DevKidCC* (Wilson, *et al.*,
256 2021). The *DevKidCC* package enables robust classification of novel developing human or
257 stem cell-derived kidney organoid datasets without the need for integration or prior
258 dimensional reduction or clustering. Using the *ComparePlot* function, the D13 and D13+14
259 samples were directly compared with respect to their kidney cell proportions. This confirmed
260 distinct differences in kidney cell populations, but consistency between the 4 replicates within
261 each sample (Figure 3C and Supplementary Figure 3A). As anticipated, over 90% of cells
262 within the D13 monolayer differentiations were classified as NPC or NPC-like, with a small
263 contribution of cells classified as early nephron. In contrast, D13+14 organoids possessed a
264 range of proximal and distal nephron cell types, as well as renal corpuscle cell types. Early
265 proximal tubule (EPT) formed the largest proportion of organoid nephron cell types (51%
266 average across 4 samples), while two replicates possessed a small (<5%) fraction of maturing
267 PT cells. By contrast, previous studies of the standard organoid protocol (Takasato *et al.*, 2015)
268 show on average <25% EPT and no PT.

269 To gain in-depth understanding of the impact of prolonged monolayer culture in CDBLY2 on
270 the identity and maturity of the resulting cell types, we firstly used *DevKidCC* to compare the
271 expression of cell type-specific markers in D13 and D13+14 samples to published stem cell-
272 derived and reference fetal kidney datasets (Figure 3D-F). Analysis of the NPC population
273 within D13 samples confirmed strong gene signatures for committed NPCs (*SIX1*, *SIX2*, and
274 *LYPD1*) and the metanephric HOX code (*HOXC10/11*, *HOXA11*, and *HOXD11*) compared to
275 relevant published monolayer and nephrogenic-stage differentiations (Subramanian, *et al.*,
276 2019; Wu, *et al.*, 2018; Low, *et al.*, 2019; Tran, *et al.*, 2019) that better emulated the mixed

277 reference dataset of week 11, 13, 16, and 18 human fetal kidneys (Hochane, *et al.*, 2019; Tran,
278 *et al.*, 2019; Holloway, *et al.*, 2020). PT-enhanced organoids derived from these D13
279 monolayer differentiations possessed high and abundant expression of a range of proximal
280 nephron markers in their EPT population (Figure 3E). These included genes encoding several
281 membrane proteins critical for proximal tubular transport of proteins and amino acids (*CUBN*,
282 *LRP2*, *SLC3A1*, and *SLC3A2*), as well as auxiliary proteins and transcription factors required
283 for transporter regulation and functionality, such as *AMN*, *AGT*, and *HNF4A*. This gene
284 signature showed remarkable congruence to reference human fetal kidney and improved PT
285 identity compared to existing published kidney organoid datasets (Czerniecki, *et al.*, 2018;
286 Harder, *et al.*, 2019; Kumar, *et al.*, 2019) (Figure 3E).

287 An important anatomical feature of the mature PT is its segmentation into functionally and
288 morphologically distinct regions defined as the S1/S2 convoluted tubule segments and the S3
289 straight segment. In addition to differences in proliferation characteristics and protein synthesis
290 (Zhuo and Li, 2013; Avissar, *et al.*, 1994), the convoluted and straight segments display distinct
291 differences in solute handling to accommodate the declining concentration of solutes as the
292 ultrafiltrate passes through the nephron. As such, early S1 – S2 convoluted segments express
293 low-affinity/high-capacity transporters, with a gradual transition to high-affinity/low-capacity
294 transporters in the later S3 straight segment (Palacin, *et al.*, 2001; Schuh, *et al.*, 2018; Verrey,
295 *et al.*, 2005). To determine whether the PTs of enhanced organoids show evidence of this
296 segmentation, PT clusters from the 4 integrated D13+14 replicate datasets were isolated and
297 re-clustered, resolving 4740 PT cells across 6 distinct clusters (Supplementary Figure 3B). The
298 PT population was analysed for the expression of segment-specific PT markers with critical
299 functional roles, including solute carriers for ions (*SLC34A1/NPT2* (Fenollar-Ferrer, *et al.*,
300 2015) expressed in S1>S2), glucose (*SLC2A2/GLUT2* and *SLC5A2/SGLT2* expressed in
301 S1>S2; *SLC2A1/GLUT1* and *SLC5A1/SGLT1* expressed in S2<S3 (Hummel, *et al.*, 2011;
302 Rahmoune, *et al.*, 2005; Wood and Trayhurn, 2003)), amino acids (*SLC7A9/b(0,+)*AT
303 transporter of cystine, aspartate, and glutamate expressed in S1/S2 > S3 (Nagamori, *et al.*,
304 2016)), and cationic drugs/toxins (*SLC47A1/MATE1* expressed in S1/S2 > S3 (Otsuka, *et al.*,
305 2005)), as well as *AKAP12* (involved in cell cycle regulation, expressed in S2<S3 (Vogetseder,
306 *et al.*, 2008) and *GPX3* (glutathione peroxidase; secreted antioxidant synthesised in S1/S2>S3
307 (Avissar, *et al.*, 1994)). UMAP plots revealed the largely opposing distributions of cells
308 expressing S1>S2 and S2>S3 gene signatures (Supplementary Figure 3C). Cells expressing
309 S1>S2 convoluted PT markers (*SLC34A1/MATE1*, *SLC2A2/GLUT2*, and *SLC5A2/SGLT2*)

310 were predominantly located in clusters 0, 3, and the lower portion of cluster 4, whereas cells
311 expressing S2<S3 straight PT markers (*AKAP12*, *SLC2A1/GLUT1*, and *SLC5A1/SGLT1*) were
312 primarily within clusters 1, 2, and the upper portion of cluster 4. When analysed for markers
313 that exhibit a gradient of expression along the length of the nephron (S1/S2>S3), UMAP plots
314 for each gene revealed a similar graded expression pattern, with a higher concentration of
315 positive cells within the S1>S2 cluster (0) and decreasing in prevalence within S2<S3 clusters
316 (0, 2) (Supplementary Figure 3C). Together this suggested that, despite the low expression of
317 some markers indicating PT immaturity, the PTs of enhanced kidney organoids show evidence
318 of separation into the 3 distinct anatomical PT segments.

319 Comparison between organoids is confounded by the inherent variability of different organoid
320 protocols, technical variables and individual cell line characteristics. To minimise potential
321 bias when comparing cell maturation, PT-enhanced organoid scRNASeq data was compared
322 to that of an iPSC line-matched organoid of equivalent organoid age (day 11 – 12 of organoid
323 culture), generated using our standard protocol but with equivalent techniques (Howden, *et al.*,
324 2019). Libraries from the PT-enhanced and standard organoid samples resolved 6737 and 1879
325 cells, respectively. Datasets were integrated prior to quality control measures to enable direct
326 comparison of PT maturation and UMAP plots confirmed the resolution of distinct kidney cell
327 clusters for both samples (Supplementary Figure 3D). Violin plots of the PT cluster alone in
328 integrated datasets confirmed that the PT-enhanced organoid dataset possessed higher and
329 more abundant expression of genes critical for PT functionality compared to the standard
330 organoid (Figure 3Fi-ii). Examples included genes encoding membrane transporters
331 *CUBILIN/CUBN* and *MEGALIN/LRP2* (important for protein uptake (Nielsen, *et al.*, 2016)),
332 heavy-chain subunit solute carriers *rBAT/SLC3A1* and *4F2/SLC3A2* (required for heteromer
333 formation and amino acid transport by *SLC7* family members (Kowalczyk, *et al.*, 2008)), light-
334 chain subunit solute carriers *y+LAT-1/SLC7A7* and *LAT2/SLC7A8* (responsible for regulating
335 intracellular amino acid pool via basolateral efflux of basic and neutral amino acids for
336 transport systems *y+L* and *L*, respectively (Kanai, *et al.*, 2000; Verrey, 2003)), and solute
337 carriers critical for PT metabolism and drug transport (*G6PT1/SLC37A4* and
338 *MATE1/SLC47A1* (Lee, *et al.*, 2015)). Several auxiliary proteins essential for correct apical
339 localisation and transporter functionality also showed higher expression in the PT-enhanced
340 dataset, including *AMN* (Amnionless), *ACE2*, and *TMEM27* (Collectrin) (Kowalczyk, *et al.*,
341 2008; Camargo, *et al.*, 2009; Fyfe, *et al.*, 2004; Ahuja, *et al.*, 2008) (Figure 3Fi). Expression
342 of genes encoding drug transporters *SLC22A2* (OCT2) and *SLC22A6* (OAT1) were low in both

343 conditions (Figure 3Fii). However, the PT-enhanced condition resulted in higher expression of
344 both transporters compared to standard.

345 To investigate PT maturation further, an unbiased ToppFun GO Molecular Function analysis
346 was performed on genes that were significantly differentially expressed within the PT cluster
347 of PT-enhanced compared to standard organoids (945 input genes). This analysis revealed key
348 differences in genes involved in cell metabolism (Figure 3G and Supplementary Figure 3E).
349 PT-enhanced organoid cells within the PT cluster showed increased expression of genes related
350 to fatty acid metabolism and its regulation, such as *PPARG*, *FABP3*, *PRKAA2*, and *FAT1*
351 (Figure 3G). Given the known reliance of mature PT cells on fatty acid metabolism *in vivo*
352 (reviewed in Zhuo and Li, 2013), this gene signature was suggestive of a more mature
353 metabolic profile in enhanced compared to standard organoid PT cells. Taken together, these
354 comprehensive scRNASeq analyses confirmed an increased abundance and relative maturation
355 of PT within this extended protocol. Analyses of D13 monolayers suggests this higher-order
356 PT patterning arises from improved NPC identity at the point of metanephric specification.

357 **Mature expression and localisation of proximal tubule proteins enables nephron** 358 **functionality**

359 To establish the maturity of PTs within enhanced organoids at a protein-level, D13+14
360 organoids were examined via immunofluorescence for expression and correct cellular
361 localisation of PT function markers (Figure 4A). Within LTL-positive tubules, organoids
362 expressed a range of critical proteins, including membrane transporters CUBILIN (CUBN),
363 MEGALIN (MEG) and SLC6A19 (Figure 4Ai – ii), as well as the nuclear transcription factor,
364 HNF4A (Figure 4Aiii). This strong expression and apical cellular localisation of transporters
365 was suggestive of nephron functionality. To test this, we firstly performed multiple substrate
366 uptake assays specific to proximal tubules (Figure 4B). PT-enhanced organoids demonstrated
367 a capacity for uptake of fluorescently labelled albumin (TRITC-albumin) specifically into
368 MEG-positive proximal tubules, indicative of CUBN-MEG transport function (Figure 4Bi). In
369 addition, these PTs also demonstrated robust uptake of 4',6-diamidino-2-phenylindole (DAPI);
370 an effective probe for evaluation of the PT-specific SLC47 family of organic cation/H⁺
371 antiporters, MATE-1 (Multidrug and Toxin Extrusion Protein 1) and MATE2-K (Multidrug
372 and Toxin Extrusion Protein 2K) (Yasujima, *et al.*, 2010) (Figure 4Bii). The uptake of DAPI
373 by PT cells was successfully inhibited via pre-treatment of organoids with Cimetidine, a cation

374 transporter inhibitor, supporting the specificity of transport activity, while the absence of
375 DRAQ7 staining excluded the possibility of DAPI uptake in PTs due to cell death.

376 Having established albumin and organic cation transport capacity, we next assessed the
377 response of PT-enhanced organoids to nephrotoxic insult. Several recent studies have explored
378 the suitability of kidney organoids as a human-relevant model of cisplatin-induced
379 nephrotoxicity (Freedman, *et al.*, 2015; Morizane, *et al.*, 2015; Takasato, *et al.*, 2015), a
380 common complication that limits usage of this chemotherapeutic agent (Ozkok and Edelstein,
381 2014; Yao, *et al.*, 2007). The biomarker KIM-1 is sensitive for early detection of PT injury in
382 humans and animals (Abdelsalam, *et al.*, 2018; Chiusolo, *et al.*, 2010; Sasaki, *et al.*, 2011;
383 Shinke, *et al.*, 2015; Vaidya, *et al.*, 2010) and has been shown to increase in response to
384 cisplatin in kidney organoids, despite conflicting reports regarding its PT-specificity
385 (Morizane, *et al.*, 2015; Takasato, *et al.*, 2016; Digby, *et al.*, 2020). This discrepancy may arise
386 from immature expression of the predominant cisplatin transporters, particularly
387 SLC22A2/OCT2 (Digby, *et al.*, 2020) combined with heterogeneity in cisplatin uptake
388 mechanisms. Re-analysis of our existing D13+14 scRNASeq data revealed low-level
389 expression of transporters for both cisplatin influx and efflux (Supplementary Figure 3F),
390 including *SLC22A2/OCT2* previously reported to show low expression in organoids (Digby, *et*
391 *al.*, 2020), suggestive of cisplatin transport capacity. To confirm the functionality of these
392 transporters and appropriate injury response by PTs, D13+14 organoids were exposed to 20
393 μ M cisplatin for 24 hours. Immunofluorescence analysis revealed upregulation of KIM-1
394 protein expression within LTL-positive PTs of enhanced organoids compared to PBS-treated
395 controls (Figure 4C). This was supported by a significant increase in the expression of *HAVCR1*
396 relative to *HNF4A* ($P = 0.003$) (Figure 4D). Together, these data confirmed efficient cisplatin
397 uptake and expected injury response.

398 **Radial nephron patterning and alignment is associated with localised WNT antagonism**

399 Of interest was the characteristic radial patterning observed in all PT-enhanced organoids,
400 where tubules align with their glomeruli towards the centre of the organoid and distal
401 SLC12A1+ segments towards the organoid periphery (refer to Figure 2B). This distinct
402 morphology and patterning was found to be strongly driven by the intensity and duration of
403 canonical WNT signalling (induced by CHIR) during the initial monolayer differentiation
404 conditions (Figure 5). While exposure of the iPSC monolayer to WNT signalling for 5 days

405 prior to CDBLY2 promoted radially-aligned PTs, exposure to the iPSCs to a reduced duration
406 of WNT signalling (4D x 7 μ M), which more closely resembled standard organoid protocols
407 (Takasato, *et al.*, 2015; Howden, *et al.*, 2019; Vanslambrouck, *et al.*, 2019) led to the generation
408 of evenly distributed patterned nephrons surrounding a GATA3-positive CNS/ureteric
409 epithelial network (Figure 5A). Closer histological examination of PT-enhanced organoids
410 revealed the nephron glomeruli to be aligned around a central interstitial core that differentiated
411 into Alcian blue-positive cartilage with prolonged organoid culture (Figure 5B).

412 Previous studies have suggested that proximo-distal patterning is controlled by Wnt/ β -catenin
413 signalling along the nephron axis, with lower WNT signalling leading to improved formation
414 and maturation of the proximal nephron (Lindstrom, *et al.*, 2015). In agreement with this, WNT
415 inhibition has been observed to promote podocyte commitment in PSC cultures (Yoshimura,
416 *et al.*, 2019). These findings suggested that the central pre-cartilage core of the PT-enhanced
417 organoids may be expressing a localised WNT antagonist influencing nephron patterning. This
418 was supported by re-analysis of our organoid scRNASeq data, confirming the expression of
419 WNT antagonists in D13+14 organoids (Supplementary Figure 4B). Secreted Frizzled-related
420 Protein 2 (sFRP2), a gene with known expression and involvement in developing kidney
421 (Lescher, *et al.*, 1998; Yoshino, *et al.*, 2001), was the most abundantly expressed antagonist
422 and displayed the highest expression levels in the cartilage clusters (clusters 2 and 5), followed
423 by stroma (Supplementary Figure 3A).

424 To test whether localised WNT antagonism has a functional impact on nephron development
425 we recreated a signalling gradient using agarose beads soaked in WNT inhibitor (10 μ M IWR-
426 1). Following the 7 day (standard) differentiation protocol, iPSC-derived kidney progenitors
427 were bioprinted and cultured to create rectangular patch organoids (Lawlor, *et al.*, 2021).
428 Following 5 days of organoid culture (D7+5) and the formation of renal vesicles, IWR-1-
429 soaked or control (PBS-soaked) beads were added to the centre of the organoids where they
430 made contact with the early epithelial structures (Supplementary Figure 4B). After 9 days of
431 organoid culture, organoids with IWR-1-soaked beads exhibited visible differences in the
432 morphology of structures surrounding the beads compared to controls (organoids with PBS-
433 soaked beads) (Supplementary Figure 3C). This became more apparent when these organoids
434 were stained via immunofluorescence (Figure 5D). In organoids exposed to PBS-soaked beads,
435 beads were in contact with a mixture of proximal and distal EPCAM-positive nephron
436 epithelium, as well as NPHS2-positive podocytes of glomeruli (Figure 5Ci). In contrast, IWR-

437 1-soaked beads were predominantly surrounded by glomeruli, with few distal (LTL-
438 negative/EPCAM-positive) visible overall (Figure 5Cii). This supports a localised WNT
439 antagonism being responsible for the nephron directionality and alignment in PT-enhanced
440 organoids.

441 **PT-enhanced organoids represent an improved model for SARS-CoV-2 pathogenesis** 442 **research**

443 Kidney organoids have previously proven useful to model inherited, early-onset kidney disease
444 (Freedman, *et al.*, 2015; Czerniecki, *et al.*, 2018; Cruz, *et al.*, 2017; Forbes, *et al.*, 2018; Hale,
445 *et al.*, 2018; Hollywood, *et al.*, 2020; Mae, *et al.*, 2013; Przepiorski, *et al.*, 2018; Taguchi and
446 Nishinakamura, 2017; Tanigawa, *et al.*, 2018). More recently, organoids have been
447 successfully applied to understanding the pathogenesis of the infectious respiratory disease
448 COVID-19, with SARS-CoV-2 viral infection and replication being achieved in a range of
449 stem cell-derived tissues (Han, *et al.*, 2020; Marchiano, *et al.*, 2021; Mills, *et al.*, 2021; Sharma,
450 *et al.*, 2020; Tiwari, *et al.*, 2021). Driven by the occurrence of AKI in COVID-19 patients
451 (Huang, *et al.*, 2020; Kunutsor and Laukkanen, 2020; Yang, *et al.*, 2020; Zhou, *et al.*, 2020), a
452 handful of studies have explored kidney organoids as a potential model of COVID-19 (Monteil,
453 *et al.*, 2020; Wysocki, *et al.*, 2021). While it is still debated whether kidney damage results
454 from direct viral infection or a combination of inflammatory responses and drug nephrotoxicity
455 (reviewed in Motavalli, *et al.*, 2021), human PTs show high expression of the key SARS-CoV-
456 2 receptor ACE2 (Kowalczyk, *et al.*, 2008; Hoffmann, *et al.*, 2020) and evidence of viral
457 infection (Braun, *et al.*, 2020; Farkash, *et al.*, 2020; Kissling, *et al.*, 2020; Puelles, *et al.*, 2020;
458 Su, *et al.*, 2020; Werion, *et al.*, 2020; Hanley, *et al.*, 2020). Given the high proportion of PT in
459 enhanced organoids, we investigated their suitability as a model of SARS-CoV-2 infection and
460 pathogenesis. Comprehensive analysis of scRNAseq data from >15,800 D13+14 organoid cells
461 revealed expression levels and cellular localisation of a range of entry factors (receptors,
462 proteases and binding proteins) previously implicated in SARS-CoV-2 infection (Amraei, *et*
463 *al.*, 2021; Singh, *et al.*, 2020) (Figure 6A). While these entry factors were predominantly
464 expressed within proximal tubule (clusters 1, 13 and 15), they were also observed in distal
465 (clusters 9 and 17) nephron segments and endothelium (cluster 16) (Figure 6A). When
466 comparing age- and line-matched organoids, all SARS-CoV-2 entry factors of the proximal
467 and distal tubular segments showed increased expression levels and abundance in PT-enhanced
468 organoids (Figure 6Bi-ii).

469 We next performed an in-depth investigation of the two most frequently reported viral entry
470 factors in literature, *ACE2/ACE2* and *TMPRSS2/TMPRSS2* (Hoffmann, *et al.*, 2020).
471 ScRNAseq and immunofluorescence demonstrated *ACE2/ACE2* expression within the PT
472 clusters of D13+14 organoids and localisation to the apical membrane of kidney organoid PTs,
473 confirming previous reports *in vivo* and in kidney organoids (Kowalczyk, *et al.*, 2008;
474 Camargo, *et al.*, 2009; Han, *et al.*, 2020; Monteil, *et al.*, 2020; Wysocki, *et al.*, 2021) (Figure
475 6AC). Apical ACE2 expression was also identified in epithelial cells lining the initial portion
476 of Bowman's capsule transitioning from the S1 segment of the PT (Supplementary Figure 5A).
477 Previous studies in mice have identified these transitional cells as cuboidal and intermediate
478 parietal epithelial cells (cuPECs and iPECs), making up the most proximal part of the proximal
479 tubule prior to transitioning to flat PECs that line Bowmans's capsule (Kuppe, *et al.*, 2019;
480 Wang, 2019). Accordingly, high *ACE2* gene expression correlated with a subset of cells co-
481 expressing general PEC markers with a cuPEC/iPEC-specific profile (PAX8+, AKAP12+,
482 PROM1-) (Supplementary Figure 5B). This region also partly coincided with the
483 SLC34A1^{Hi}/HNF4A⁺/SLC36A2⁺ population marking early (S1) PT cells (Lee, *et al.*, 2015;
484 Broer, *et al.*, 2008) (Supplementary Figure 5C), which, along with LTL-positivity of the early
485 Bowmans capsule epithelium (Supplementary Figure 5A), agreed with the known S1-PEC
486 transitional phenotype reported for cPECs and iPECs (Kuppe, *et al.*, 2019).

487 In contrast to a previous report in kidney organoids (Wysocki, *et al.*, 2021), *ACE2* and
488 *TMPRSS2* were not co-expressed, instead being present within distinct nephron segments
489 (proximal and distal, respectively), as has been observed in non-human primate kidney (Han,
490 *et al.*, 2020) (Figure). *ACE2* was also absent from podocytes (cluster 12) (Figure 6A). To ensure
491 this lack of co-expression was not the result of 'dropout' (failure to detect an expressed gene
492 in single cell RNAseq), imputation was performed using Markov Affinity-based Graph
493 Imputation of Cells (MAGIC; (van Dijk, *et al.*, 2018)). MAGIC-generated scatter plots
494 confirmed a strong correlation (high R² linear correlation value) of *ACE2* and *TMPRSS2* with
495 proximal tubule and distal tubule markers, respectively (Supplementary Figure 6A). This
496 expression pattern was further supported by analyses of human fetal kidney, with expression
497 of *ACE2* and *TMPRSS2*, along with additional SARS-CoV-2 entry factors, exhibiting a highly
498 similar expression pattern to our extended kidney organoids (Supplementary Figure 6B). Using
499 immunofluorescence, ACE2 protein was confirmed to reside on the apical membrane of
500 organoid PTs, as observed in human kidney (Figure 6C) (Kowalczyk, *et al.*, 2008), in contrast

501 to the predominantly basolateral localisation of TMPRSS2 in distal tubule (Figure 6C and
502 Supplementary Figure 6B). This would suggest viral entry is not reliant on TMPRSS2.

503 Having confirmed the expression of viral entry factors, PT-enhanced organoids were assessed
504 for infectivity and viral replication following incubation in SARS-CoV-2 inoculum. Viral
505 replication was detected in 3 independent replicate experiments as early as 2 days post-
506 infection, with titres significantly increased compared to mock-infected organoids by day 6
507 post-infection ($P = 0.006$) (Figure 7A). Compared to standard organoids, PT-enhanced
508 organoids showed higher levels of viral replication at 2 days post infection, reaching
509 significance at 4 days post-infection ($P = 0.0253$), across independent experiments replicated
510 using the same iPSC line and organoid conditions (Figure 7B). To determine the kidney cell
511 types targeted by SARS-CoV-2, infected organoids were analysed via immunofluorescence for
512 double stranded RNA (dsRNA) and nephron-specific markers 6 days post-infection (Figure
513 7C). DsRNA was observed predominantly in LTL-positive proximal tubules, as well as
514 Bowman's capsule surrounding NPHS1-positive podocytes and portions of SLC12A1-positive
515 Loops of Henle (Figure 7Ci-iii). No dsRNA was present in NPHS1-positive podocytes (Figure
516 7Fii), supporting ACE2 as the likely entry factor based on gene expression profiles (Figure
517 6A).

518

519 Discussion

520 The utility of human pluripotent stem cell-derived kidney organoids as models of kidney
521 disease will rely upon nephron functional maturation. This is most critical for kidney organoid
522 proximal tubules which, to date, have not shown significant evidence of functional solute
523 transport. In this study, we show that changes to the initial maintenance of the nephron
524 progenitor population, together with an inhibition of premature epithelialisation, results in
525 improved proximal tubule maturation and unique alignment of nephrons along the
526 proximodistal axis. This spatial arrangement is likely attributed to a WNT signalling gradient
527 from the centre to the periphery of the organoid arising from the production of WNT inhibitors,
528 including sFRP2, inducing a central ring of glomeruli from which sequential S1/S2 and S3 PT
529 patterning occurs. This reinforces the requirement for a proximodistal gradient of WNT
530 signalling for appropriate nephron patterning and segmentation.

531 While supporting a more proximal tubular phenotype, there was a bias away from distal tubule
532 elements. Of importance, transcriptional profiling of D13 monolayers showed a high
533 proportion of nephron progenitors with a significant increase in nephron progenitor gene
534 expression (*SIX1*, *LYPD1*) and metanephric HOX ortholog expression (*HOX11A/C/D*) in
535 comparison to all other comparable scRNASeq datasets. One of the unique features of this
536 modified protocol includes the addition of nephron progenitor maintenance media, most
537 importantly to prolong WNT agonism at low levels (C), suppress NOTCH signalling (D), and
538 increase BMP7 activity (B). In agreement with this, mouse studies have shown a requirement
539 for Notch to initiate nephron progenitor commitment (Boyle, *et al.*, 2011), with Notch
540 signalling also required for nephron formation and Notch2 proposed to support proximal
541 nephron patterning (Chung, *et al.*, 2017; Surendran, *et al.*, 2010). Low levels of canonical Wnt
542 activity and Bmp/BMP signalling via MAPK and PI3K pathways have also been proposed to
543 support nephron progenitor survival (Brown, *et al.*, 2015; Karner, *et al.*, 2011; Park, *et al.*,
544 2007; Blank, *et al.*, 2009; Lindstrom, *et al.*, 2015; Muthukrishnan, *et al.*, 2015). Despite
545 containing both low CHIR and BMP7, the alternate nephron progenitor maintenance media
546 NPSR was unable to support subsequent nephron formation in the resulting organoids.
547 However, this may have been impacted by other variations in this media, such as the inclusion
548 of BMP and TGF β receptor inhibitors (dual inhibition of SMAD1/5/8 and SMAD2/3) (Li, *et*
549 *al.*, 2016), which may maintain a less competent nephron progenitor population (Tanigawa, *et*
550 *al.*, 2019).

551 PT-enhanced organoid formation had a less critical requirement for LIF (L) and Rho-kinase
552 (ROCK) inhibition (Y). ROCK inhibition has previously been shown to prevent nephron
553 patterning and elongation (Lindstrom, *et al.*, 2013). LIF has been suggested to induce
554 mesenchymal-to-epithelial conversion (Barasch, *et al.*, 1999) but reduce the formation of
555 developed nephrons (Bard and Ross, 1991). However, its effect may be somewhat complicated
556 by concentration, with low LIF suggested to promote nephron progenitor expansion in culture
557 via maintaining nuclear SIX2 and YAP, critical for self-renewal (Tanigawa, *et al.*, 2015).
558 Timing of exposure remains an additional confounding factor, with the majority of growth
559 factor requirement studies being performed in *ex vivo* cultured mouse or rat explants already
560 possessing epithelializing structures within the mesenchyme.

561 It remains to be seen whether the outcome of this enhanced differentiation is a result of
562 improved nephron progenitor expansion or sufficient time to form a more metanephric nephron
563 progenitor population. Recent studies of the relative timing of PSC differentiation suggest that
564 development and maturation *in vitro* is influenced by a predetermined species-specific
565 biological clock. This has been elegantly demonstrated by Matsuda *et al* (2020), showing that
566 the markedly different paces of differentiation exhibited by mouse and human PSCs can be
567 attributed to biochemical rate variations that influence the segmentation clock (Matsuda, *et al.*,
568 2020). Indeed, brain organoids require months in culture to develop specific neural subtypes,
569 akin to human gestation (Lancaster, *et al.*, 2013; Velasco, *et al.*, 2019). While our PT-enhanced
570 kidney organoid protocol already shows considerable improvements in maturation after only 3
571 – 4 weeks, there is likely room for additional improvements in PT maturation that require
572 optimisation of metabolic conditions beyond this time.

573 PT-enhanced kidney organoids do not simply show enhanced PT maturation, but also increased
574 numbers of cells committed to a PT identity based on the HNF4A^{YFP} iPSC reporter line.
575 Furthermore, this is the first report of functional proximal tubules within spatially aligned
576 nephrons. We show that this is likely the response to a central zone of localised WNT
577 antagonism likely emanating from the stroma. As such, the organoids appear to establish a sink
578 and source of WNT activity along the length of the tubule which mimics the WNT signalling
579 gradient required for appropriate proximodistal patterning (Lindstrom, *et al.*, 2015). The
580 formation of a cartilage-forming stroma is problematic from the perspective of regenerating a
581 transplantable tissue and has also been observed to form spontaneously after the transplantation
582 of organoids generated using a number of distinct protocols (Bantounas, *et al.*, 2020; Nam, *et*

583 *al.*, 2019; van den Berg, *et al.*, 2018). It is possible that this cartilage arises from paraxial
584 mesoderm present within the culture, despite there being no increase in PARAXIS expression
585 compared to standard (D7) monolayer differentiations of the same age. Alternatively, this may
586 be a side-effect of the prolonged BMP signalling which could potentially be suppressed through
587 SMAD1/5/8 inhibition. Nevertheless, the enhanced proximal tubular expansion, segmentation,
588 and maturation afforded by establishing a signalling gradient through localised WNT
589 antagonism represents a superior approach for the study of proximal tubule responses.

590 A clear example of the utility of such organoids for modelling infectious disease is illustrated
591 with the infection of PT-enhanced organoids with SARS-CoV-2. Our data shows an improved
592 capacity to infect PT-enhanced organoids with increased expression of previously identified
593 viral entry factors. In contrast to previous studies, we show no evidence for a dual requirement
594 for TMPRSS2 and ACE2 for PT infection, given the separation in both cell type distribution
595 and apical-basal protein insertion between these two proteins. However, analysis of dsRNA
596 staining suggests that SARS-CoV-2 can enter distal portions of the nephron, suggesting
597 multiple entry pathways are at play. Establishing such entry mechanisms are of keen interest
598 to the renal community. ACE2 binding by SARS-CoV-2 results in a downregulation of the
599 renin angiotensin system (RAS) by reducing the conversion of angiotensin I (Ang I) and
600 angiotensin II (Ang II) to phosphorylated products angiotensin 1-9 and angiotensin 1-7,
601 respectively (reviewed in Silhol, *et al.*, 2020). This leads to higher plasma concentrations of
602 Ang I and subsequently Ang II (via angiotensin converting enzyme; ACE), increased binding
603 of Ang II to its receptor (AT1R), and activation of systemic responses such as vasoconstriction,
604 aldosterone secretion stimulation, hypokalemia, inflammation, and fibrosis (Silhol, *et al.*, 2020;
605 Reddy, *et al.*, 2019). As such, the renal community has been interested to know whether renal
606 failure patients on ACE inhibitors (control Ang I/II conversion) are at greater or less risk of
607 renal damage in response to COVID-19 (Diaz, 2020; Esler and Esler, 2020; Fang, *et al.*, 2020;
608 Hippisley-Cox, *et al.*, 2020; Li, *et al.*, 2021; Vaduganathan, *et al.*, 2020).

609 The PT-enhanced organoid model provides an opportunity to evaluate the impact of viral entry,
610 ACE2 expression level, and the response of cells to ACE inhibition during infection. However,
611 this model may also provide a superior testbed for screening of different SARS-CoV-2 variants
612 in addition to other viral infections of the kidney such as BK virus, a major challenge in
613 immunosuppressed kidney transplant recipients (Herrera, *et al.*, 2021). While previous adult
614 kidney tubuloids have been infected with BK virus (Schutgens, *et al.*, 2019), the definitive

615 identity of these tubules is not clear. As such, the maturity and distinct S1/S2/S3 segmentation
616 within PT-enhanced organoids, along with evidence for distal nephron, offer a unique
617 opportunity to study viral mechanisms. These advantages, combined with the suitability of PT-
618 enhanced kidney organoids to elicit the appropriate response to drug-induced injury, makes
619 this an ideal platform for disease research applications while providing insight into improving
620 our control over the spatial organisation of bioengineered tissue.

621

622

623

624

625 **Methods**

626 *iPSC lines and maintenance*

627 iPSC lines used in this study include CRL1502.C32 (Takasato, *et al.*, 2015; Briggs, *et al.*, 2013)
628 CRL-2429/SIX2^{Cre/Cre}:GAPDH^{dual} (Howden, *et al.*, 2019), PCS-201-010/HNF4A^{YFP}
629 (Vanslambrouck, *et al.*, 2019), and PB010/MCRIi010-A (Vlahos, *et al.*, 2019). All iPSC lines
630 were maintained and expanded at 37°C, 5% CO₂ and 5% O₂ in Essential 8 medium (Thermo
631 Fisher Scientific, Waltham, MA) on Matrigel- (BioStrategy, Victoria, Australia) coated plates
632 with daily media changes and passaged every 2 – 3 days with EDTA in 1X PBS as described
633 previously (Chen, *et al.*, 2011).

634 *Directed differentiation and kidney organoid generation*

635 For standard organoid production, differentiation of iPSC lines and organoid culture was
636 performed as described previously (Howden, *et al.*, 2019), with minor variations in the
637 concentration of Laminin-521 (BioLamina, Sundbyberg, Sweden) used to coat 12-well plates,
638 initial iPSC seeding density within 12-well plates, and CHIR99021 (R&D Systems)
639 concentration and duration of exposure according to the iPSC line used (CRL1502.C32, CRL-
640 2429/SIX2^{Cre/Cre}:GAPDH^{dual} and PB010/MCRIi010-A were seeded at 25,000 cells/well and
641 exposed to 6µM CHIR for 5 days; PCS-201-010/HNF4A^{YFP} was seeded at 40,000 cells/well
642 and exposed to 6µM CHIR for 4 days; CRL1502.C32, CRL-2429/SIX2^{Cre/Cre}:GAPDH^{dual} were
643 seeded with 20µL/mL Laminin-521; PB010/MCRIi010-A and PCS-201-010/HNF4A^{YFP} were
644 seeded with 40µL/mL Laminin-521). Standard bioprinted patch organoids were generated as
645 described previously (Lawlor, *et al.*, 2021).

646 For PT-enhanced organoids, Matrigel concentrations and iPSC seeding density for
647 differentiation in 12-well plates were as stated for standard organoids above. iPSCs were then
648 subjected to prolonged monolayer differentiation in 6µM CHIR for 5 days, followed by
649 200ng/mL FGF9 (R&D Systems) and 1µg/mL heparin (Sigma Aldrich) until day 8, refreshing
650 the media every second day. At day 8, the monolayer was exposed to 1mL/well nephron
651 progenitor maintenance media, NPSR or CDBLY (Li, *et al.*, 2016; Tanigawa, *et al.*, 2016),
652 refreshing these media daily. Final PT-enhanced organoid conditions utilised CDBLY2,

653 containing 2X concentration of BMP7. Organoids were generated and cultured as described
654 previously (Takasato, *et al.*, 2016).

655 ***Immunofluorescence and confocal microscopy***

656 For immunofluorescence, organoids were prepared and stained as previously described
657 (Vanslambrouck, *et al.*, 2019) using the antibodies detailed in Table 1, diluted in 0.1% TX-
658 100/PBS. Imaging was performed on the ZEISS LSM 780 confocal microscope (Carl Zeiss,
659 Oberkochen, Germany) with acquisition and processing performed using ZEISS ZEN Black
660 software (Zeiss Microscopy, Thornwood, NY) and Fiji ImageJ (Schindelin, *et al.*, 2012).

661 ***Flow cytometry***

662 Flow cytometry of reporter line-derived organoids using endogenous fluorescence was
663 performed and analysed as described previously (Vanslambrouck, *et al.*, 2019). To determine
664 the contribution of SIX2-mCherry + cells to EPCAM+ populations in organoids derived from
665 the SIX2^{Cre} lineage tracing iPSC line, dissociated and strained cells were stained using directly
666 conjugated anti-EPCAM Alexa Fluor-647 antibody (see Table 1) diluted 1:100 in 100 μ L of
667 FACS wash (1% fetal calf serum [FCS] in PBS) for every 5×10^5 cells. Following 30 minutes
668 incubation on ice, cells were washed 3 times in 2mL FACS wash via centrifugation prior to
669 flow cytometry.

670 ***Histology***

671 For Alcian Blue detection of cartilage, organoids were fixed in 4% PFA as described above
672 and processed for routine paraffin embedding using the Excelsior AS Tissue Processor (rapid
673 biopsy setting; Thermo Fisher Scientific). Samples were embedded in wax and 5 μ m sections
674 cut using a Waterfall HM325 microtome (Thermo Fisher Scientific). Sections were dewaxed,
675 hydrated through graded alcohols to running water, then covered with Alcian Blue Solution
676 (1% Alcian blue in 3% acetic acid, pH 2.5). After 10 minutes, sections were washed in tap
677 water for 2 minutes and counterstained for 7 minutes in Nuclear Fast Red stain (0.1% Nuclear
678 Fast Red [Sigma Aldrich, St Louise, MO] and 5% ammonium potassium sulfate in water).
679 Following staining, sections were dehydrated in graded alcohols, cleared in Saffsolvent (Bacto

680 Laboratories, NSW, Australia), and coverslipped. Images were acquired on a Zeiss Axio
681 Imager A2 with Zeiss Zen software (Zeiss Microscopy, Thornwood, NY).

682 ***Real-time quantitative reverse transcription PCR (qRT-PCR)***

683 RNA extraction, cDNA synthesis and quantitative RT-PCR (qRT-PCR) were performed using
684 the Bioline Isolate II Mini/Micro RNA Extraction Kit, SensiFAST cDNA Synthesis Kit and
685 the SensiFAST SYBR Lo-ROX Kit (Bioline, NSW, Australia), respectively, as per
686 manufacturer's instructions. Each qRT-PCR reaction was performed in triplicate using the
687 primer pairs detailed in Table 2. Data were graphed and analysed in Prism 8 (GraphPad).

688 ***Single cell RNA sequencing (scRNAseq) and dataset generation***

689 The D13+12 dataset was generated using the CRL-2429/SIX2^{Cre/Cre}:GAPDH^{dual} iPSC line. The
690 D13 and D13+14 organoids were generated using the CRL1502.C32 with four replicates per
691 time point, where each replicate was derived from an independent well. Cells were dissociated
692 following previously published methods (Lawlor, *et al.*, 2021). For the D13 and D13+14
693 samples, replicates were multiplexed following the method of Soeckius *et al.* (Stoeckius, *et al.*,
694 2018). Cells were stained for 20 minutes on ice with 1 µg of BioLegend TotalSeq-A anti-human
695 hashtag oligo antibody (BioLegend TotalSeq-A0251 to A0258). Cells were washed 3 times
696 then pooled at equal ratios for sequencing. A single library was generated for each
697 suspension/condition, composed of equally sized pools of each replicate (Set 1 – 4). Libraries
698 were generated following the standard 10x Chromium Next GEM Single Cell 3' Reagent Kits
699 v3.1 protocol except that 'superloading' of the 10x device was performed with ~30k cells. Hash
700 tag oligo (HTO) libraries were generated following the BioLegend manufacturer protocol.
701 Sequencing was performed using an Illumina Novoseq.

702 10x mRNA libraries were demultiplexed using CellRanger (3.1.0) to generate matrices of UMI
703 counts per cell. HTO libraries were demultiplexed using Cite-seq-count (1.4.3) to generate
704 matrices of HTO counts per cell barcode. All data were loaded into Seurat (3.1.4) and HTO
705 libraries were matched to mRNA libraries. Seurat was used to normalise HTO counts and
706 determine cut-offs to assign HTO identity per cell using the *HTODemux* function with the
707 *positive.quantile* parameter set at 0.99. HTO doublet and unassigned cells were removed, as
708 were cells with mitochondrial content greater than 35% accounting for the increased metabolic

709 activity of renal epithelium (Ransick, *et al.*, 2019), number of genes per cell greater than 500
710 and the number of UMIs less than 100000, to obtain filtered datasets (D13 replicates: 3694
711 cells [A0251], 3545 cells [A0252], 3785 cells [A0253], 3641 cells [A0254]; D13+14 replicates:
712 3415 cells [A0255], 2350 cells [A0256], 2904 cells [A0257], 2578 cells [A0258]). The
713 combined datasets contained a median of 3915 genes expressed per cell, with a median of
714 16352 UMI counts per cell.

715 *Analysis of scRNAseq datasets*

716 Data was normalised using the SCTransform method (Hafemeister and Satija, 2019) including
717 the regression of cell cycle scores. A 30 component Principal Component Analysis (PCA) was
718 performed, followed by Uniform Manifold Approximation and Projection (UMAP) using these
719 PCA components. Seurat's graph-based clustering approach was used to identify, with
720 resolutions of 0.7 (D13) and 0.5 (D13+14) chosen for downstream analysis. Marker analysis
721 was performed using the Seurat *FindMarkers* function, using student's t-test, limited to positive
722 markers (i.e. increased expression within a cluster) above 0.25 log fold-change expressed in at
723 least 10% of cells within a cluster. Marker lists were exported and cluster identities were
724 determined by comparison with published human single cell data (Howden, *et al.*, 2019) or
725 Gene ontology analysis using ToppFun (<https://toppgene.cchmc.org/enrichment.jsp>). The
726 proximal tubule cluster was isolated and reanalysed as above to further investigate any
727 subpopulations.

728 The D13+12 dataset was integrated with an age- and line-matched published dataset (Howden,
729 *et al.*, 2019) using the anchor-based method within Seurat (Butler, *et al.*, 2018; Stuart, *et al.*,
730 2019). This integrated dataset was analysed as above, isolating the proximal tubule cluster and
731 comparing gene expression of cells from both samples within this population.

732 For DevKidCC analyses, the D13 and D13p14 samples were analysed using DevKidCC
733 (v.0.2.2); a hierarchical set of machine-learning binary classifiers trained on a human fetal
734 kidney reference dataset. The classified dataset was then compared to relevant existing single
735 cell organoid datasets using the *DotPlotCompare* function.

736 *Agarose bead-mediated morphogen signalling assay*

737 Bioprinted patch organoids were generated and cultured as described previously prior to the
738 addition of morphogen-soaked beads at D7+5 (Lawlor, *et al.*, 2021). The day before bead
739 addition, 100 μ L of Affi-Gel Blue Gel 100 – 200 mesh crosslinked agarose beads (Bio-Rad
740 Laboratories, Hercules, CA), were washed 3 times in PBS via centrifugation. Washed beads
741 were resuspended in 100 μ L of PBS (control) or 10 μ M IWR-1 (stock reconstituted according
742 to manufacturer's instructions; Sigma Aldrich) and incubated for 1 hour at room temperature
743 prior to overnight storage at 4°C. On day 7+5, suspensions were agitated to resuspend beads
744 and 0.3 μ L was added to the centre of each patch organoid with the aid of a P2 pipette and
745 dissecting microscope (Leica Microsystems, Wetzlar, Germany). Organoid media (TeSR-E6
746 [STEMCELL Technologies, Vancouver, Canada]) was refreshed every second day prior to
747 harvest at D7+9 for immunofluorescence.

748 ***Cisplatin toxicity assay***

749 D13+14 PT-enhanced organoids were exposed through the basolateral compartment of the
750 Transwell tissue culture plate (Corning Incorporated, Corning, NY) to 1mL per well of 20 μ M
751 Cisplatin (Accord Healthcare, Durham, NC), or an equivalent volume of PBS, in TeSR-E6 for
752 24 hours (37°C, 5% CO₂ and 5% O₂). Following incubation, organoids within Transwells were
753 washed with PBS and harvested for flow cytometry as described above.

754 ***Fluorescent substrate uptake assays***

755 For albumin uptake assays, D13+14 PT-enhanced organoids (triplicate wells per condition)
756 were incubated in TRITC albumin (1:1000, Sigma Aldrich) and anti-MEGALIN/LRP2 (1:500,
757 pre-incubated with an alpaca Nano-secondary Alexa Fluor 647 secondary antibody diluted in
758 TeSR-E6 culture media via the basolateral compartment of Transwell tissue culture plates and
759 incubated overnight (37°C, 5% CO₂ and 5% O₂). Control organoids were incubated in
760 secondary antibody alone. After incubation, plates containing organoids were washed in at least
761 3 changes of Hanks' Balanced Salt Solution (HBSS; Thermo Fisher Scientific) for 30 minutes
762 and live-imaged immediately using a ZEISS LSM 780 confocal microscope. For organic
763 cation transport assays, D13+14 PT-enhanced organoids (triplicate wells per condition) were
764 incubated in 4',6-diamindino-2-phenylindole substrate (DAPI; 1:1000 [Thermo Fisher
765 Scientific]) with 1:500 DRAQ7 dead cell label (Thermo Fisher Scientific) diluted in TeSR-E6
766 for 1 hour (37°C, 5% CO₂ and 5% O₂). Control organoids were pre-incubated for 15 minutes

767 in 100 μ M Cimetidine inhibitor (Sigma Aldrich) prior to incubation for 1 hour in TeSR-E6
768 containing both inhibitor, substrate, and dead cell label (1:1000 DAPI, 1:500 DRAQ7, 100 μ M
769 Cimetidine). Following incubation, substrate and substrate + inhibitor solutions were replaced
770 with HBSS and live-imaged immediately using a ZEISS LSM 780 confocal microscope.

771 *Viral infection assays*

772 Standard and PT-enhanced organoids grown on Transwells were infected with 10^4 tissue-
773 culture infectious dose 50 (TCID₅₀) of SARS-CoV-2 (Australia/VIC01/2020) in TeSR-E6
774 media, added either above or below the Transwell, for 1 – 3 hours (37°C and 5% CO₂).
775 Following incubation, the viral inoculum was removed and replaced with 1mL of plain TeSR-
776 E6 medium beneath the Transwell as for typical organoid culture (Takasato, *et al.*, 2016).
777 Culture medium was collected on days 0, 2, 4, and 6 post-infection for viral titer quantification
778 and replaced with fresh medium. Median TCID₅₀ in supernatants were determined, as detailed
779 below, by 10- fold serial dilution in Vero cells and calculated using the Reed and Muench
780 method. Organoids were harvested at 6 days post-infection and and fixed with 4% PFA fixation
781 for immunofluorescence.

782 *Infectious virus titration (TCID₅₀)*

783 Viral titrations were performed on confluent monolayers of Vero cells in 96-well plates. Wells
784 were washed with plain minimum essential media (MEM) and replaced with 180 μ l of infection
785 media (MEM, 50U/ml Penicillin, 50 μ g/ml Streptomycin, 2mM GlutaMax, 15mM HEPES and
786 1 μ g/ml TPCK-treated Trypsin). 20 μ l of the samples to be titred were added to four wells and
787 10-fold serial dilutions were made. Plates were incubated at 37°C and 5% CO₂. Four days post-
788 infection, SARS-CoV-2-induced cytopathic effect was assessed by microscopy.

789

790

791

792 **Tables**

793 **Table 1.** Antibodies used in immunofluorescence studies.

Specificity	Host species	Dilution range	Manufacturer and identifier
ACE2	Rabbit	1:300	Abcam (ab15348)
CUBILIN	Goat	1:300	Santa Cruz Biotechnology (sc-20607)
dsRNA	Mouse	1:300	Absolute Antibody (Ab01299-2.0)
ECADHERIN	Mouse	1:300	BD Biosciences (610181)
EpCAM (Alexa488 or Alexa647 conjugate)	Mouse	1:300	BioLegend (324210 and 324212)
GATA3	Goat or rabbit	1:300	R&D Systems (AF2605) and Cell Signalling Technology (95852S)
HNF4A	Mouse	1:300	Life Technologies (MA1-199)
KIM-1	Goat	1:300	R&D Systems (AF1750)
mCherry (RFP)	Rabbit	1:300 – 1:400	MBL Medical & Biological Laboratories Co. Ltd. (PM005)
MEGALIN	Rabbit	1:300	Sapphire Bioscience (NBP2-39033)
NEPHRIN	Sheep	1:300	R&D Systems (AF4269)
Proximal tubule brush border membrane	<i>Lotus tetragonobulus</i> lectin (LTL)	1:300 – 1:500	Vector Laboratories (B-1325)
TMPRSS2	Mouse	1:300	Merck (MABF2158-25UG)
SLC6A19	Chicken	1:100 – 1:200	Aves Laboratories (custom antibody)
SLC12A1	Rabbit	1:300 – 1:400	Proteintech (18970-1-AP)

794

795 **Table 2.** Forward and reverse primers used for qRT-PCR.

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
<i>DAPL1</i>	CTCGGAAAGGGGGACATCCT	AGTTGAGCTTCTCCAGTGCG

<i>GAPDH</i>	CTCTCTGCTCCTCCTGTTCGA	TGAGCGATGTGGCTCGGCT
<i>GATA3</i>	GCCCCCATTAAAGCCCAAG	TTGTGGTGGTCTGACAGTTCG
<i>HAVCR1</i>	GTTCTCCAATGCCTTTGCC	CGGTGTCATTCCCATCTGTTG
<i>HNF4A</i>	ACCCTCGTCGACATGGACA	GCCTTCTGATGGGGACGTG
<i>HOXD11</i>	GCCAGTGTGCTGTCGTTCCC	CTTCCTACAGACCCCGCCGT
<i>LHX1</i>	CGTCATTCAGGTCTGGTTCC	CCCGTAGTACTCGCTCTGGT
<i>PARAXIS</i>	GGGGGTGGCCGTCGT	CAGGCTGAATGGATCCTCAC
<i>SIX1</i>	AAAGGGAAGGAGAACAAGGATAG	GGAGCCTACATGATTACTGGG
<i>SIX2</i>	TCCTGGTCCCTCCGTATGTA	TAGGGGCAGATAGACCACCA
<i>TMEM-100</i>	CAGGCGTTGCTGTTTCTTGT	CAGGGTGAAAGCTCGGAGAG
<i>WNT4</i>	AACTGCTCCACACTCGACTC	TGACCACTGGAAGCCCTGT

796

797 **Acknowledgements**

798 We thank Maelle Le Moing and the Murdoch Children's Research Institute Translational
799 Genomics Unit for 10x single cell and hash-tag oligo library preparation and sequencing, and
800 bulk-RNAseq sequencing; Dr Matthew Burton and the Murdoch Children's Research Institute
801 Microscopy Core; Professor John Rasko and Dr Charles Bailey for providing the SLC6A19
802 antibody.

803 **Author Contributions**

804 JMV, MHL, and KS contributed to experimental design and planning. JMV, KST, EG, RR,
805 JN, MS, and SEH performed experiments and developed reagents and methods. SBW and JMV
806 performed bioinformatics analyses. JMV, MHL, and SBW contributed to manuscript
807 preparation. JMV and MHL wrote the manuscript.

808 **Data availability**

809 All transcriptional profiling datasets have been submitted to GEO (GSE184928). These
810 including single cell RNAseq from D13 monolayer differentiation, D13+14 PT-enhanced
811 kidney organoids, and D13+12 PT-enhanced kidney organoid.

812 **Competing interests**

813 The authors declare they have no competing interests.

814 **References**

815 1 Collaboration, G. B. D. C. K. D. Global, regional, and national burden of chronic kidney
816 disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
817 *Lancet* **395**, 709-733, doi:10.1016/S0140-6736(20)30045-3 (2020).

818 2 Kirita, Y., Wu, H., Uchimura, K., Wilson, P. C. & Humphreys, B. D. Cell profiling of
819 mouse acute kidney injury reveals conserved cellular responses to injury. *Proc Natl*
820 *Acad Sci U S A* **117**, 15874-15883, doi:10.1073/pnas.2005477117 (2020).

821 3 Zhuo, J. L. & Li, X. C. Proximal nephron. *Compr Physiol* **3**, 1079-1123,
822 doi:10.1002/cphy.c110061 (2013).

823 4 Freedman, B. S., Brooks, C. R., Lam, A. Q., Fu, H., Morizane, R., Agrawal, V., Saad,
824 A. F., Li, M. K., Hughes, M. R., Werff, R. V., Peters, D. T., Lu, J., Baccei, A., Siedlecki,
825 A. M., Valerius, M. T., Musunuru, K., McNagny, K. M., Steinman, T. I., Zhou, J.,
826 Lerou, P. H. & Bonventre, J. V. Modelling kidney disease with CRISPR-mutant kidney
827 organoids derived from human pluripotent epiblast spheroids. *Nature communications*
828 **6**, 8715, doi:10.1038/ncomms9715 (2015).

829 5 Morizane, R., Lam, A. Q., Freedman, B. S., Kishi, S., Valerius, M. T. & Bonventre, J.
830 V. Nephron organoids derived from human pluripotent stem cells model kidney
831 development and injury. *Nature biotechnology* **33**, 1193-1200, doi:10.1038/nbt.3392
832 (2015).

833 6 Taguchi, A., Kaku, Y., Ohmori, T., Sharmin, S., Ogawa, M., Sasaki, H. &
834 Nishinakamura, R. Redefining the in vivo origin of metanephric nephron progenitors
835 enables generation of complex kidney structures from pluripotent stem cells. *Cell Stem*
836 *Cell* **14**, 53-67, doi:10.1016/j.stem.2013.11.010 (2014).

- 837 7 Toyohara, T., Mae, S., Sueta, S., Inoue, T., Yamagishi, Y., Kawamoto, T., Kasahara,
838 T., Hoshina, A., Toyoda, T., Tanaka, H., Araoka, T., Sato-Otsubo, A., Takahashi, K.,
839 Sato, Y., Yamaji, N., Ogawa, S., Yamanaka, S. & Osafune, K. Cell Therapy Using
840 Human Induced Pluripotent Stem Cell-Derived Renal Progenitors Ameliorates Acute
841 Kidney Injury in Mice. *Stem cells translational medicine* **4**, 980-992,
842 doi:10.5966/sctm.2014-0219 (2015).
- 843 8 Combes, A. N., Phipson, B., Lawlor, K. T., Dorison, A., Patrick, R., Zappia, L., Harvey,
844 R. P., Oshlack, A. & Little, M. H. Single cell analysis of the developing mouse kidney
845 provides deeper insight into marker gene expression and ligand-receptor crosstalk.
846 *Development* **146**, doi:10.1242/dev.178673 (2019).
- 847 9 Howden, S. E., Wilson, S. B., Groenewegen, E., Starks, L., Forbes, T. A., Tan, K. S.,
848 Vanslambrouck, J. M., Holloway, E. M., Chen, Y. H., Jain, S., Spence, J. R. & Little,
849 M. H. Plasticity of distal nephron epithelia from human kidney organoids enables the
850 induction of ureteric tip and stalk. *Cell Stem Cell* **28**, 671-684 e676,
851 doi:10.1016/j.stem.2020.12.001 (2021).
- 852 10 Subramanian, A., Sidhom, E. H., Emani, M., Vernon, K., Sahakian, N., Zhou, Y., Kost-
853 Alimova, M., Slyper, M., Waldman, J., Dionne, D., Nguyen, L. T., Weins, A., Marshall,
854 J. L., Rosenblatt-Rosen, O., Regev, A. & Greka, A. Single cell census of human kidney
855 organoids shows reproducibility and diminished off-target cells after transplantation.
856 *Nature communications* **10**, 5462, doi:10.1038/s41467-019-13382-0 (2019).
- 857 11 Wu, H., Uchimura, K., Donnelly, E. L., Kirita, Y., Morris, S. A. & Humphreys, B. D.
858 Comparative Analysis and Refinement of Human PSC-Derived Kidney Organoid
859 Differentiation with Single-Cell Transcriptomics. *Cell Stem Cell* **23**, 869-881 e868,
860 doi:10.1016/j.stem.2018.10.010 (2018).
- 861 12 Takasato, M., Er, P. X., Chiu, H. S., Maier, B., Baillie, G. J., Ferguson, C., Parton, R.
862 G., Wolvetang, E. J., Roost, M. S., Chuva de Sousa Lopes, S. M. & Little, M. H. Kidney
863 organoids from human iPS cells contain multiple lineages and model human
864 nephrogenesis. *Nature* **526**, 564-568, doi:10.1038/nature15695 (2015).
- 865 13 Takasato, M., Er, P. X., Chiu, H. S. & Little, M. H. Generation of kidney organoids
866 from human pluripotent stem cells. *Nature protocols* **11**, 1681-1692,
867 doi:10.1038/nprot.2016.098 (2016).

- 868 14 Marable, S. S., Chung, E. & Park, J. S. Hnf4a Is Required for the Development of Cdh6-
869 Expressing Progenitors into Proximal Tubules in the Mouse Kidney. *J Am Soc Nephrol*
870 **31**, 2543-2558, doi:10.1681/ASN.2020020184 (2020).
- 871 15 Wilson, S. B., Howden, S. E., Vanslambrouck, J. M., Dorison, A., Alquicira-
872 Hernandez, J., Powell, J. E. & Little, M. H. DevKidCC allows for robust classification
873 and direct comparisons of kidney organoid datasets. *bioRxiv*,
874 doi:10.1101/2021.01.20.427346 (2021).
- 875 16 Dressler, G. R. Advances in early kidney specification, development and patterning.
876 *Development* **136**, 3863-3874, doi:10.1242/dev.034876 (2009).
- 877 17 de Bakker, B. S., van den Hoff, M. J. B., Vize, P. D. & Oostra, R. J. The Pronephros; a
878 Fresh Perspective. *Integr Comp Biol* **59**, 29-47, doi:10.1093/icb/icz001 (2019).
- 879 18 Kobayashi, A., Valerius, M. T., Mugford, J. W., Carroll, T. J., Self, M., Oliver, G. &
880 McMahon, A. P. Six2 defines and regulates a multipotent self-renewing nephron
881 progenitor population throughout mammalian kidney development. *Cell Stem Cell* **3**,
882 169-181, doi:10.1016/j.stem.2008.05.020 (2008).
- 883 19 Lindstrom, N. O., McMahon, J. A., Guo, J., Tran, T., Guo, Q., Rutledge, E., Parvez, R.
884 K., Saribekyan, G., Schuler, R. E., Liao, C., Kim, A. D., Abdelhalim, A., Ruffins, S.
885 W., Thornton, M. E., Baskin, L., Grubbs, B., Kesselman, C. & McMahon, A. P.
886 Conserved and Divergent Features of Human and Mouse Kidney Organogenesis. *J Am*
887 *Soc Nephrol* **29**, 785-805, doi:10.1681/ASN.2017080887 (2018).
- 888 20 Georgas, K. M., Chiu, H. S., Lesieur, E., Rumballe, B. A. & Little, M. H. Expression
889 of metanephric nephron-patterning genes in differentiating mesonephric tubules. *Dev*
890 *Dyn* **240**, 1600-1612, doi:10.1002/dvdy.22640 (2011).
- 891 21 Mugford, J. W., Sipila, P., Kobayashi, A., Behringer, R. R. & McMahon, A. P. Hoxd11
892 specifies a program of metanephric kidney development within the intermediate
893 mesoderm of the mouse embryo. *Dev Biol* **319**, 396-405,
894 doi:10.1016/j.ydbio.2008.03.044 (2008).
- 895 22 Tiedemann, K., Welling, L. W. & Basto, P. Structural and functional comparison of
896 mesonephric and metanephric proximal tubules. *Pediatr Nephrol* **1**, 297-305,
897 doi:10.1007/BF00849227 (1987).

- 898 23 Howden, S. E., Vanslambrouck, J. M., Wilson, S. B., Tan, K. S. & Little, M. H.
899 Reporter-based fate mapping in human kidney organoids confirms nephron lineage
900 relationships and reveals synchronous nephron formation. *EMBO Rep*,
901 doi:10.15252/embr.201847483 (2019).
- 902 24 Vanslambrouck, J. M., Wilson, S. B., Tan, K. S., Soo, J. Y., Scurr, M., Spijker, H. S.,
903 Starks, L. T., Neilson, A., Cui, X., Jain, S., Little, M. H. & Howden, S. E. A Toolbox
904 to Characterize Human Induced Pluripotent Stem Cell-Derived Kidney Cell Types and
905 Organoids. *J Am Soc Nephrol* **30**, 1811-1823, doi:10.1681/ASN.2019030303 (2019).
- 906 25 Little, M. H. & Combes, A. N. Kidney organoids: accurate models or fortunate
907 accidents. *Genes Dev* **33**, 1319-1345, doi:10.1101/gad.329573.119 (2019).
- 908 26 Tsujimoto, H., Kasahara, T., Sueta, S. I., Araoka, T., Sakamoto, S., Okada, C., Mae, S.
909 I., Nakajima, T., Okamoto, N., Taura, D., Nasu, M., Shimizu, T., Ryosaka, M., Li, Z.,
910 Sone, M., Ikeya, M., Watanabe, A. & Osafune, K. A Modular Differentiation System
911 Maps Multiple Human Kidney Lineages from Pluripotent Stem Cells. *Cell reports* **31**,
912 107476, doi:10.1016/j.celrep.2020.03.040 (2020).
- 913 27 Brown, A. C., Muthukrishnan, S. D. & Oxburgh, L. A synthetic niche for nephron
914 progenitor cells. *Developmental cell* **34**, 229-241, doi:10.1016/j.devcel.2015.06.021
915 (2015).
- 916 28 Li, Z., Araoka, T., Wu, J., Liao, H. K., Li, M., Lazo, M., Zhou, B., Sui, Y., Wu, M. Z.,
917 Tamura, I., Xia, Y., Beyret, E., Matsusaka, T., Pastan, I., Rodriguez Esteban, C.,
918 Guillen, I., Guillen, P., Campistol, J. M. & Izpisua Belmonte, J. C. 3D Culture Supports
919 Long-Term Expansion of Mouse and Human Nephrogenic Progenitors. *Cell Stem Cell*
920 **19**, 516-529, doi:10.1016/j.stem.2016.07.016 (2016).
- 921 29 Tanigawa, S., Sharma, N., Hall, M. D., Nishinakamura, R. & Perantoni, A. O.
922 Preferential Propagation of Competent SIX2+ Nephronic Progenitors by LIF/ROCKi
923 Treatment of the Metanephric Mesenchyme. *Stem Cell Reports* **5**, 435-447,
924 doi:10.1016/j.stemcr.2015.07.015 (2015).
- 925 30 Tanigawa, S., Taguchi, A., Sharma, N., Perantoni, A. O. & Nishinakamura, R. Selective
926 In Vitro Propagation of Nephron Progenitors Derived from Embryos and Pluripotent
927 Stem Cells. *Cell reports* **15**, 801 - 813, doi:10.1016/j.celrep.2016.03.076 (2016).

- 928 31 Lindstrom, N. O., Lawrence, M. L., Burn, S. F., Johansson, J. A., Bakker, E. R.,
929 Ridgway, R. A., Chang, C. H., Karolak, M. J., Oxburgh, L., Headon, D. J., Sansom, O.
930 J., Smits, R., Davies, J. A. & Hohenstein, P. Integrated beta-catenin, BMP, PTEN, and
931 Notch signalling patterns the nephron. *Elife* **3**, e04000, doi:10.7554/eLife.04000
932 (2015).
- 933 32 Takasato, M., Er, P. X., Becroft, M., Vanslambrouck, J. M., Stanley, E. G., Elefanty,
934 A. G. & Little, M. H. Directing human embryonic stem cell differentiation towards a
935 renal lineage generates a self-organizing kidney. *Nature cell biology* **16**, 118-126,
936 doi:10.1038/ncb2894 (2014).
- 937 33 Hochane, M., van den Berg, P. R., Fan, X., Berenger-Currias, N., Adegeest, E.,
938 Bialecka, M., Nieveen, M., Menschaart, M., Chuva de Sousa Lopes, S. M. & Semrau,
939 S. Single-cell transcriptomics reveals gene expression dynamics of human fetal kidney
940 development. *PLoS Biol* **17**, e3000152, doi:10.1371/journal.pbio.3000152 (2019).
- 941 34 Lindstrom, N. O., De Sena Brandine, G., Tran, T., Ransick, A., Suh, G., Guo, J., Kim,
942 A. D., Parvez, R. K., Ruffins, S. W., Rutledge, E. A., Thornton, M. E., Grubbs, B.,
943 McMahon, J. A., Smith, A. D. & McMahon, A. P. Progressive Recruitment of
944 Mesenchymal Progenitors Reveals a Time-Dependent Process of Cell Fate Acquisition
945 in Mouse and Human Nephrogenesis. *Developmental cell* **45**, 651-660 e654,
946 doi:10.1016/j.devcel.2018.05.010 (2018).
- 947 35 Lindstrom, N. O., Guo, J., Kim, A. D., Tran, T., Guo, Q., De Sena Brandine, G.,
948 Ransick, A., Parvez, R. K., Thornton, M. E., Basking, L., Grubbs, B., McMahon, J. A.,
949 Smith, A. D. & McMahon, A. P. Conserved and Divergent Features of Mesenchymal
950 Progenitor Cell Types within the Cortical Nephrogenic Niche of the Human and Mouse
951 Kidney. *J Am Soc Nephrol* **29**, 806-824, doi:10.1681/ASN.2017080890 (2018).
- 952 36 Lindstrom, N. O., Tran, T., Guo, J., Rutledge, E., Parvez, R. K., Thornton, M. E.,
953 Grubbs, B., McMahon, J. A. & McMahon, A. P. Conserved and Divergent Molecular
954 and Anatomic Features of Human and Mouse Nephron Patterning. *J Am Soc Nephrol*
955 **29**, 825-840, doi:10.1681/ASN.2017091036 (2018).
- 956 37 Low, J. H., Li, P., Chew, E. G. Y., Zhou, B., Suzuki, K., Zhang, T., Lian, M. M., Liu,
957 M., Aizawa, E., Rodriguez Esteban, C., Yong, K. S. M., Chen, Q., Campistol, J. M.,
958 Fang, M., Khor, C. C., Foo, J. N., Izpisua Belmonte, J. C. & Xia, Y. Generation of

- 959 Human PSC-Derived Kidney Organoids with Patterned Nephron Segments and a De
960 Novo Vascular Network. *Cell Stem Cell* **25**, 373-387 e379,
961 doi:10.1016/j.stem.2019.06.009 (2019).
- 962 38 Tran, T., Lindstrom, N. O., Ransick, A., De Sena Brandine, G., Guo, Q., Kim, A. D.,
963 Der, B., Peti-Peterdi, J., Smith, A. D., Thornton, M., Grubbs, B., McMahon, J. A. &
964 McMahon, A. P. In Vivo Developmental Trajectories of Human Podocyte Inform In
965 Vitro Differentiation of Pluripotent Stem Cell-Derived Podocytes. *Developmental cell*
966 **50**, 102-116 e106, doi:10.1016/j.devcel.2019.06.001 (2019).
- 967 39 Holloway, E. M., Wu, J. H., Czerwinski, M., Sweet, C. W., Wu, A., Tsai, Y. H., Huang,
968 S., Stoddard, A. E., Capeling, M. M., Glass, I. & Spence, J. R. Differentiation of Human
969 Intestinal Organoids with Endogenous Vascular Endothelial Cells. *Developmental cell*
970 **54**, 516-528 e517, doi:10.1016/j.devcel.2020.07.023 (2020).
- 971 40 Czerniecki, S. M., Cruz, N. M., Harder, J. L., Menon, R., Annis, J., Otto, E. A., Gulieva,
972 R. E., Islas, L. V., Kim, Y. K., Tran, L. M., Martins, T. J., Pippin, J. W., Fu, H., Kretzler,
973 M., Shankland, S. J., Himmelfarb, J., Moon, R. T., Paragas, N. & Freedman, B. S. High-
974 Throughput Screening Enhances Kidney Organoid Differentiation from Human
975 Pluripotent Stem Cells and Enables Automated Multidimensional Phenotyping. *Cell*
976 *Stem Cell* **22**, 929-940 e924, doi:10.1016/j.stem.2018.04.022 (2018).
- 977 41 Harder, J. L., Menon, R., Otto, E. A., Zhou, J., Eddy, S., Wys, N. L., O'Connor, C.,
978 Luo, J., Nair, V., Cebrian, C., Spence, J. R., Bitzer, M., Troyanskaya, O. G., Hodgins, J.
979 B., Wiggins, R. C., Freedman, B. S., Kretzler, M., European Renal c, D. N. A. B. &
980 Nephrotic Syndrome Study, N. Organoid single cell profiling identifies a transcriptional
981 signature of glomerular disease. *JCI Insight* **4**, doi:10.1172/jci.insight.122697 (2019).
- 982 42 Kumar, S. V., Er, P. X., Lawlor, K. T., Motazedian, A., Scurr, M., Ghobrial, I., Combes,
983 A. N., Zappia, L., Oshlack, A., Stanley, E. G. & Little, M. H. Kidney micro-organoids
984 in suspension culture as a scalable source of human pluripotent stem cell-derived
985 kidney cells. *Development* **146**, doi:10.1242/dev.172361 (2019).
- 986 43 Avissar, N., Ornt, D. B., Yagil, Y., Horowitz, S., Watkins, R. H., Kerl, E. A., Takahashi,
987 K., Palmer, I. S. & Cohen, H. J. Human kidney proximal tubules are the main source
988 of plasma glutathione peroxidase. *Am J Physiol* **266**, C367-375,
989 doi:10.1152/ajpcell.1994.266.2.C367 (1994).

- 990 44 Palacin, M., Fernandez, E., Chillaron, J. & Zorzano, A. The amino acid transport system
991 b(o,+) and cystinuria. *Mol Membr Biol* **18**, 21-26 (2001).
- 992 45 Schuh, C. D., Polesel, M., Platonova, E., Haenni, D., Gassama, A., Tokonami, N.,
993 Ghazi, S., Bugarski, M., Devuyt, O., Ziegler, U. & Hall, A. M. Combined Structural
994 and Functional Imaging of the Kidney Reveals Major Axial Differences in Proximal
995 Tubule Endocytosis. *J Am Soc Nephrol* **29**, 2696-2712, doi:10.1681/ASN.2018050522
996 (2018).
- 997 46 Verrey, F., Ristic, Z., Romeo, E., Ramadan, T., Makrides, V., Dave, M. H., Wagner, C.
998 A. & Camargo, S. M. Novel renal amino acid transporters. *Annu Rev Physiol* **67**, 557-
999 572, doi:10.1146/annurev.physiol.67.031103.153949 (2005).
- 1000 47 Fenollar-Ferrer, C., Forster, I. C., Patti, M., Knoepfel, T., Werner, A. & Forrest, L. R.
1001 Identification of the first sodium binding site of the phosphate cotransporter NaPi-IIa
1002 (SLC34A1). *Biophys J* **108**, 2465-2480, doi:10.1016/j.bpj.2015.03.054 (2015).
- 1003 48 Hummel, C. S., Lu, C., Loo, D. D., Hirayama, B. A., Voss, A. A. & Wright, E. M.
1004 Glucose transport by human renal Na⁺/D-glucose cotransporters SGLT1 and SGLT2.
1005 *Am J Physiol Cell Physiol* **300**, C14-21, doi:10.1152/ajpcell.00388.2010 (2011).
- 1006 49 Rahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G. & Brown, J.
1007 Glucose transporters in human renal proximal tubular cells isolated from the urine of
1008 patients with non-insulin-dependent diabetes. *Diabetes* **54**, 3427-3434,
1009 doi:10.2337/diabetes.54.12.3427 (2005).
- 1010 50 Wood, I. S. & Trayhurn, P. Glucose transporters (GLUT and SGLT): expanded families
1011 of sugar transport proteins. *Br J Nutr* **89**, 3-9, doi:10.1079/BJN2002763 (2003).
- 1012 51 Nagamori, S., Wiriyasermkul, P., Guarch, M. E., Okuyama, H., Nakagomi, S.,
1013 Tadagaki, K., Nishinaka, Y., Bodoy, S., Takafuji, K., Okuda, S., Kurokawa, J., Ohgaki,
1014 R., Nunes, V., Palacin, M. & Kanai, Y. Novel cystine transporter in renal proximal
1015 tubule identified as a missing partner of cystinuria-related plasma membrane protein
1016 rBAT/SLC3A1. *Proc Natl Acad Sci USA* **113**, 775-780, doi:10.1073/pnas.1519959113
1017 (2016).
- 1018 52 Otsuka, M., Matsumoto, T., Morimoto, R., Arioka, S., Omote, H. & Moriyama, Y. A
1019 human transporter protein that mediates the final excretion step for toxic organic

- 1020 cations. *Proc Natl Acad Sci U S A* **102**, 17923-17928, doi:10.1073/pnas.0506483102
1021 (2005).
- 1022 53 Vogetseder, A., Picard, N., Gaspert, A., Walch, M., Kaissling, B. & Le Hir, M.
1023 Proliferation capacity of the renal proximal tubule involves the bulk of differentiated
1024 epithelial cells. *Am J Physiol Cell Physiol* **294**, C22-28,
1025 doi:10.1152/ajpcell.00227.2007 (2008).
- 1026 54 Nielsen, R., Christensen, E. I. & Birn, H. Megalin and cubilin in proximal tubule protein
1027 reabsorption: from experimental models to human disease. *Kidney Int* **89**, 58-67,
1028 doi:10.1016/j.kint.2015.11.007 (2016).
- 1029 55 Kowalczyk, S., Broer, A., Tietze, N., Vanslambrouck, J. M., Rasko, J. E. & Broer, S.
1030 A protein complex in the brush-border membrane explains a Hartnup disorder allele.
1031 *FASEB J* **22**, 2880-2887, doi:fj.08-107300 [pii]
1032 10.1096/fj.08-107300 (2008).
- 1033 56 Kanai, Y., Fukasawa, Y., Cha, S. H., Segawa, H., Chairoungdua, A., Kim, D. K.,
1034 Matsuo, H., Kim, J. Y., Miyamoto, K., Takeda, E. & Endou, H. Transport properties of
1035 a system y⁺L neutral and basic amino acid transporter. Insights into the mechanisms of
1036 substrate recognition. *J Biol Chem* **275**, 20787-20793, doi:10.1074/jbc.M000634200
1037 (2000).
- 1038 57 Verrey, F. System L: heteromeric exchangers of large, neutral amino acids involved in
1039 directional transport. *Pflügers Arch* **445**, 529-533, doi:10.1007/s00424-002-0973-z
1040 (2003).
- 1041 58 Lee, J. W., Chou, C. L. & Knepper, M. A. Deep Sequencing in Microdissected Renal
1042 Tubules Identifies Nephron Segment-Specific Transcriptomes. *J Am Soc Nephrol* **26**,
1043 2669-2677, doi:10.1681/ASN.2014111067 (2015).
- 1044 59 Camargo, S. M., Singer, D., Makrides, V., Huggel, K., Pos, K. M., Wagner, C. A.,
1045 Kuba, K., Danilczyk, U., Skovby, F., Kleta, R., Penninger, J. M. & Verrey, F. Tissue-
1046 specific amino acid transporter partners ACE2 and collectrin differentially interact with
1047 hartnup mutations. *Gastroenterology* **136**, 872-882, doi:10.1053/j.gastro.2008.10.055
1048 (2009).

- 1049 60 Fyfe, J. C., Madsen, M., Hojrup, P., Christensen, E. I., Tanner, S. M., de la Chapelle,
1050 A., He, Q. & Moestrup, S. K. The functional cobalamin (vitamin B12)-intrinsic factor
1051 receptor is a novel complex of cubilin and amnionless. *Blood* **103**, 1573-1579,
1052 doi:10.1182/blood-2003-08-2852 (2004).
- 1053 61 Ahuja, R., Yammani, R., Bauer, J. A., Kalra, S., Seetharam, S. & Seetharam, B.
1054 Interactions of cubilin with megalin and the product of the amnionless gene (AMN):
1055 effect on its stability. *Biochem J* **410**, 301-308, doi:10.1042/BJ20070919 (2008).
- 1056 62 Yasujima, T., Ohta, K. Y., Inoue, K., Ishimaru, M. & Yuasa, H. Evaluation of 4',6-
1057 diamidino-2-phenylindole as a fluorescent probe substrate for rapid assays of the
1058 functionality of human multidrug and toxin extrusion proteins. *Drug Metab Dispos* **38**,
1059 715-721, doi:10.1124/dmd.109.030221 (2010).
- 1060 63 Ozkok, A. & Edelstein, C. L. Pathophysiology of cisplatin-induced acute kidney injury.
1061 *Biomed Res Int* **2014**, 967826, doi:10.1155/2014/967826 (2014).
- 1062 64 Yao, X., Panichpisal, K., Kurtzman, N. & Nugent, K. Cisplatin nephrotoxicity: a
1063 review. *Am J Med Sci* **334**, 115-124, doi:10.1097/MAJ.0b013e31812dfe1e (2007).
- 1064 65 Abdelsalam, M., Elmorsy, E., Abdelwahab, H., Algohary, O., Naguib, M., El Wahab,
1065 A. A., Eldeeb, A., Eltoraby, E., Abdelsalam, A., Sabry, A., El-Metwally, M., Akl, M.,
1066 Anber, N., El Sayed Zaki, M., Almutairi, F. & Mansour, T. Urinary biomarkers for
1067 early detection of platinum based drugs induced nephrotoxicity. *BMC Nephrol* **19**, 219,
1068 doi:10.1186/s12882-018-1022-2 (2018).
- 1069 66 Chiusolo, A., Defazio, R., Zanetti, E., Mongillo, M., Mori, N., Cristofori, P. & Trevisan,
1070 A. Kidney injury molecule-1 expression in rat proximal tubule after treatment with
1071 segment-specific nephrotoxics: a tool for early screening of potential kidney
1072 toxicity. *Toxicol Pathol* **38**, 338-345, doi:10.1177/0192623310362244 (2010).
- 1073 67 Sasaki, D., Yamada, A., Umeno, H., Kurihara, H., Nakatsuji, S., Fujihira, S., Tsubota,
1074 K., Ono, M., Moriguchi, A., Watanabe, K. & Seki, J. Comparison of the course of
1075 biomarker changes and kidney injury in a rat model of drug-induced acute kidney
1076 injury. *Biomarkers* **16**, 553-566, doi:10.3109/1354750X.2011.613123 (2011).
- 1077 68 Shinke, H., Masuda, S., Togashi, Y., Ikemi, Y., Ozawa, A., Sato, T., Kim, Y. H.,
1078 Mishima, M., Ichimura, T., Bonventre, J. V. & Matsubara, K. Urinary kidney injury

- 1079 molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of
1080 cisplatin-induced nephrotoxicity in lung cancer patients. *Cancer Chemother Pharmacol*
1081 **76**, 989-996, doi:10.1007/s00280-015-2880-y (2015).
- 1082 69 Vaidya, V. S., Ozer, J. S., Dieterle, F., Collings, F. B., Ramirez, V., Troth, S.,
1083 Muniappa, N., Thudium, D., Gerhold, D., Holder, D. J., Bobadilla, N. A., Marrer, E.,
1084 Perentes, E., Cordier, A., Vonderscher, J., Maurer, G., Goering, P. L., Sistare, F. D. &
1085 Bonventre, J. V. Kidney injury molecule-1 outperforms traditional biomarkers of
1086 kidney injury in preclinical biomarker qualification studies. *Nature biotechnology* **28**,
1087 478-485, doi:10.1038/nbt.1623 (2010).
- 1088 70 Digby, J. L. M., Vanichapol, T., Przepiorski, A., Davidson, A. J. & Sander, V.
1089 Evaluation of cisplatin-induced injury in human kidney organoids. *Am J Physiol Renal*
1090 *Physiol* **318**, F971-F978, doi:10.1152/ajprenal.00597.2019 (2020).
- 1091 71 Yoshimura, Y., Taguchi, A., Tanigawa, S., Yatsuda, J., Kamba, T., Takahashi, S.,
1092 Kurihara, H., Mukoyama, M. & Nishinakamura, R. Manipulation of Nephron-
1093 Patterning Signals Enables Selective Induction of Podocytes from Human Pluripotent
1094 Stem Cells. *J Am Soc Nephrol* **30**, 304-321, doi:10.1681/ASN.2018070747 (2019).
- 1095 72 Lescher, B., Haenig, B. & Kispert, A. sFRP-2 is a target of the Wnt-4 signaling pathway
1096 in the developing metanephric kidney. *Dev Dyn* **213**, 440-451,
1097 doi:10.1002/(SICI)1097-0177(199812)213:4<440::AID-AJA9>3.0.CO;2-6 (1998).
- 1098 73 Yoshino, K., Rubin, J. S., Higinbotham, K. G., Uren, A., Anest, V., Plisov, S. Y. &
1099 Perantoni, A. O. Secreted Frizzled-related proteins can regulate metanephric
1100 development. *Mech Dev* **102**, 45-55, doi:10.1016/s0925-4773(01)00282-9 (2001).
- 1101 74 Lawlor, K. T., Vanslambrouck, J. M., Higgins, J. W., Chambon, A., Bishard, K., Arndt,
1102 D., Er, P. X., Wilson, S. B., Howden, S. E., Tan, K. S., Li, F., Hale, L. J., Shepherd, B.,
1103 Pentoney, S., Presnell, S. C., Chen, A. E. & Little, M. H. Cellular extrusion bioprinting
1104 improves kidney organoid reproducibility and conformation. *Nat Mater* **20**, 260-271,
1105 doi:10.1038/s41563-020-00853-9 (2021).
- 1106 75 Cruz, N. M., Song, X., Czerniecki, S. M., Gulieva, R. E., Churchill, A. J., Kim, Y. K.,
1107 Winston, K., Tran, L. M., Diaz, M. A., Fu, H., Finn, L. S., Pei, Y., Himmelfarb, J. &
1108 Freedman, B. S. Organoid cystogenesis reveals a critical role of microenvironment in

- 1109 human polycystic kidney disease. *Nat Mater* **16**, 1112-1119, doi:10.1038/nmat4994
1110 (2017).
- 1111 76 Forbes, T. A., Howden, S. E., Lawlor, K., Phipson, B., Maksimovic, J., Hale, L.,
1112 Wilson, S., Quinlan, C., Ho, G., Holman, K., Bennetts, B., Crawford, J., Trnka, P.,
1113 Oshlack, A., Patel, C., Mallett, A., Simons, C. & Little, M. H. Patient-iPSC-Derived
1114 Kidney Organoids Show Functional Validation of a Ciliopathic Renal Phenotype and
1115 Reveal Underlying Pathogenetic Mechanisms. *Am J Hum Genet* **102**, 816-831,
1116 doi:10.1016/j.ajhg.2018.03.014 (2018).
- 1117 77 Hale, L. J., Howden, S. E., Phipson, B., Lonsdale, A., Er, P. X., Ghobrial, I., Hosawi,
1118 S., Wilson, S., Lawlor, K. T., Khan, S., Oshlack, A., Quinlan, C., Lennon, R. & Little,
1119 M. H. 3D organoid-derived human glomeruli for personalised podocyte disease
1120 modelling and drug screening. *Nature communications* **9**, 5167, doi:10.1038/s41467-
1121 018-07594-z (2018).
- 1122 78 Hollywood, J. A., Przepiorski, A., D'Souza, R. F., Sreebhavan, S., Wolvetang, E. J.,
1123 Harrison, P. T., Davidson, A. J. & Holm, T. M. Use of Human Induced Pluripotent
1124 Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition
1125 Combination Therapy for Cystinosis. *J Am Soc Nephrol* **31**, 962-982,
1126 doi:10.1681/ASN.2019070712 (2020).
- 1127 79 Mae, S., Shono, A., Shiota, F., Yasuno, T., Kajiwara, M., Gotoda-Nishimura, N., Arai,
1128 S., Sato-Otubo, A., Toyoda, T., Takahashi, K., Nakayama, N., Cowan, C. A., Aoi, T.,
1129 Ogawa, S., McMahon, A. P., Yamanaka, S. & Osafune, K. Monitoring and robust
1130 induction of nephrogenic intermediate mesoderm from human pluripotent stem cells.
1131 *Nature communications* **4**, 1367, doi:10.1038/ncomms2378 (2013).
- 1132 80 Przepiorski, A., Sander, V., Tran, T., Hollywood, J. A., Sorrenson, B., Shih, J. H.,
1133 Wolvetang, E. J., McMahon, A. P., Holm, T. M. & Davidson, A. J. A Simple
1134 Bioreactor-Based Method to Generate Kidney Organoids from Pluripotent Stem Cells.
1135 *Stem Cell Reports* **11**, 470-484, doi:10.1016/j.stemcr.2018.06.018 (2018).
- 1136 81 Taguchi, A. & Nishinakamura, R. Higher-Order Kidney Organogenesis from
1137 Pluripotent Stem Cells. *Cell Stem Cell* **21**, 730-746 e736,
1138 doi:10.1016/j.stem.2017.10.011 (2017).

- 1139 82 Tanigawa, S., Islam, M., Sharmin, S., Naganuma, H., Yoshimura, Y., Haque, F., Era,
1140 T., Nakazato, H., Nakanishi, K., Sakuma, T., Yamamoto, T., Kurihara, H., Taguchi, A.
1141 & Nishinakamura, R. Organoids from Nephrotic Disease-Derived iPSCs Identify
1142 Impaired NEPHRIN Localization and Slit Diaphragm Formation in Kidney Podocytes.
1143 *Stem Cell Reports* **11**, 727-740, doi:10.1016/j.stemcr.2018.08.003 (2018).
- 1144 83 Han, L., Wei, X., Liu, C., Volpe, G., Wang, Z., Pan, T., Yuan, Y., Lei, Y., Lai, Y.,
1145 Ward, C., Yu, Y., Wang, M., Shi, Q., Wu, T., Wu, L., Liu, Y., Wang, C., Zhang, Y.,
1146 Sun, H., Yu, H., Zhuang, Z., Tang, T., Huang, Y., Lu, H., Xu, L., Xu, J., Cheng, M.,
1147 Liu, Y., Wong, C. W., Tan, T., Ji, W., Maxwell, P. H., Yang, H., Wang, J., Zhu, S., Liu,
1148 S., Xu, X., Hou, Y., Esteban, M. A., Liu, L. & Consortium, S. C. G. B. A.-S. C. Single-
1149 cell atlas of a non-human primate reveals new pathogenic mechanisms of COVID-19.
1150 2020.2004.2010.022103, doi:10.1101/2020.04.10.022103 %J bioRxiv (2020).
- 1151 84 Marchiano, S., Hsiang, T. Y., Khanna, A., Higashi, T., Whitmore, L. S., Bargehr, J.,
1152 Davaapil, H., Chang, J., Smith, E., Ong, L. P., Colzani, M., Reinecke, H., Yang, X.,
1153 Pabon, L., Sinha, S., Najafian, B., Sniadecki, N. J., Bertero, A., Gale, M., Jr. & Murry,
1154 C. E. SARS-CoV-2 Infects Human Pluripotent Stem Cell-Derived Cardiomyocytes,
1155 Impairing Electrical and Mechanical Function. *Stem Cell Reports* **16**, 478-492,
1156 doi:10.1016/j.stemcr.2021.02.008 (2021).
- 1157 85 Mills, R. J., Humphrey, S. J., Fortuna, P. R. J., Lor, M., Foster, S. R., Quaiife-Ryan, G.
1158 A., Johnston, R. L., Dumenil, T., Bishop, C., Rudraraju, R., Rawle, D. J., Le, T., Zhao,
1159 W., Lee, L., Mackenzie-Kludas, C., Mehdiabadi, N. R., Halliday, C., Gilham, D., Fu,
1160 L., Nicholls, S. J., Johansson, J., Sweeney, M., Wong, N. C. W., Kulikowski, E.,
1161 Sokolowski, K. A., Tse, B. W. C., Devilee, L., Voges, H. K., Reynolds, L. T.,
1162 Krumeich, S., Mathieson, E., Abu-Bonsrah, D., Karavendzas, K., Griffen, B., Titmarsh,
1163 D., Elliott, D. A., McMahon, J., Suhrbier, A., Subbarao, K., Porrello, E. R., Smyth, M.
1164 J., Engwerda, C. R., MacDonald, K. P. A., Bald, T., James, D. E. & Hudson, J. E. BET
1165 inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2
1166 infection. *Cell* **184**, 2167-2182 e2122, doi:10.1016/j.cell.2021.03.026 (2021).
- 1167 86 Sharma, A., Garcia, G., Jr., Wang, Y., Plummer, J. T., Morizono, K., Arumugaswami,
1168 V. & Svendsen, C. N. Human iPSC-Derived Cardiomyocytes Are Susceptible to
1169 SARS-CoV-2 Infection. *Cell Rep Med* **1**, 100052, doi:10.1016/j.xcrm.2020.100052
1170 (2020).

- 1171 87 Tiwari, S. K., Wang, S., Smith, D., Carlin, A. F. & Rana, T. M. Revealing Tissue-
1172 Specific SARS-CoV-2 Infection and Host Responses using Human Stem Cell-Derived
1173 Lung and Cerebral Organoids. *Stem Cell Reports* **16**, 437-445,
1174 doi:10.1016/j.stemcr.2021.02.005 (2021).
- 1175 88 Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu,
1176 X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao,
1177 Y., Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J. & Cao, B.
1178 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
1179 *Lancet* **395**, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020).
- 1180 89 Kunutsor, S. K. & Laukkanen, J. A. Renal complications in COVID-19: a systematic
1181 review and meta-analysis. *Ann Med* **52**, 345-353, doi:10.1080/07853890.2020.1790643
1182 (2020).
- 1183 90 Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M.,
1184 Yu, T., Wang, Y., Pan, S., Zou, X., Yuan, S. & Shang, Y. Clinical course and outcomes
1185 of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-
1186 centered, retrospective, observational study. *Lancet Respir Med* **8**, 475-481,
1187 doi:10.1016/S2213-2600(20)30079-5 (2020).
- 1188 91 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu,
1189 X., Guan, L., Wei, Y., Li, H., Wu, X., Xu, J., Tu, S., Zhang, Y., Chen, H. & Cao, B.
1190 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in
1191 Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054-1062,
1192 doi:10.1016/S0140-6736(20)30566-3 (2020).
- 1193 92 Monteil, V., Kwon, H., Prado, P., Hagelkruys, A., Wimmer, R. A., Stahl, M., Leopoldi,
1194 A., Garreta, E., Hurtado Del Pozo, C., Prosper, F., Romero, J. P., Wirnsberger, G.,
1195 Zhang, H., Slutsky, A. S., Conder, R., Montserrat, N., Mirazimi, A. & Penninger, J. M.
1196 Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-
1197 Grade Soluble Human ACE2. *Cell* **181**, 905-913 e907, doi:10.1016/j.cell.2020.04.004
1198 (2020).
- 1199 93 Wysocki, J., Ye, M., Hassler, L., Gupta, A. K., Wang, Y., Nicoleascu, V., Randall, G.,
1200 Wertheim, J. A. & Batlle, D. A Novel Soluble ACE2 Variant with Prolonged Duration

- 1201 of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. *J Am Soc*
1202 *Nephrol*, doi:10.1681/ASN.2020101537 (2021).
- 1203 94 Motavalli, R., Abdelbasset, W. K., Rahman, H. S., Achmad, M. H., Sergeevna, N. K.,
1204 Zekiy, A. O., Adili, A., Khiavi, F. M., Marofi, F., Yousefi, M., Ghoreishizadeh, S.,
1205 Shomali, N., Etemadi, J. & Jarahian, M. The lethal internal face of the coronaviruses:
1206 Kidney tropism of the SARS, MERS, and COVID19 viruses. *IUBMB Life* **73**, 1005-
1207 1015, doi:10.1002/iub.2516 (2021).
- 1208 95 Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S.,
1209 Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Muller, M. A., Drosten, C. &
1210 Pohlmann, S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
1211 Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278,
1212 doi:10.1016/j.cell.2020.02.052 (2020).
- 1213 96 Braun, F., Lutgehetmann, M., Pfefferle, S., Wong, M. N., Carsten, A., Lindenmeyer,
1214 M. T., Norz, D., Heinrich, F., Meissner, K., Wichmann, D., Kluge, S., Gross, O.,
1215 Pueschel, K., Schroder, A. S., Edler, C., Aepfelbacher, M., Puelles, V. G. & Huber, T.
1216 B. SARS-CoV-2 renal tropism associates with acute kidney injury. *Lancet* **396**, 597-
1217 598, doi:10.1016/S0140-6736(20)31759-1 (2020).
- 1218 97 Farkash, E. A., Wilson, A. M. & Jentzen, J. M. Ultrastructural Evidence for Direct
1219 Renal Infection with SARS-CoV-2. *J Am Soc Nephrol* **31**, 1683-1687,
1220 doi:10.1681/ASN.2020040432 (2020).
- 1221 98 Kissling, S., Rotman, S., Gerber, C., Halfon, M., Lamoth, F., Comte, D., Lhopitallier,
1222 L., Sadallah, S. & Fakhouri, F. Collapsing glomerulopathy in a COVID-19 patient.
1223 *Kidney Int* **98**, 228-231, doi:10.1016/j.kint.2020.04.006 (2020).
- 1224 99 Puelles, V. G., Lutgehetmann, M., Lindenmeyer, M. T., Sperhake, J. P., Wong, M. N.,
1225 Allweiss, L., Chilla, S., Heinemann, A., Wanner, N., Liu, S., Braun, F., Lu, S., Pfefferle,
1226 S., Schroder, A. S., Edler, C., Gross, O., Glatzel, M., Wichmann, D., Wiech, T., Kluge,
1227 S., Pueschel, K., Aepfelbacher, M. & Huber, T. B. Multiorgan and Renal Tropism of
1228 SARS-CoV-2. *N Engl J Med* **383**, 590-592, doi:10.1056/NEJMc2011400 (2020).
- 1229 100 Su, H., Yang, M., Wan, C., Yi, L. X., Tang, F., Zhu, H. Y., Yi, F., Yang, H. C., Fogo,
1230 A. B., Nie, X. & Zhang, C. Renal histopathological analysis of 26 postmortem findings

- 1231 of patients with COVID-19 in China. *Kidney Int* **98**, 219-227,
1232 doi:10.1016/j.kint.2020.04.003 (2020).
- 1233 101 Werion, A., Belkhir, L., Perrot, M., Schmit, G., Aydin, S., Chen, Z., Penaloza, A., De
1234 Greef, J., Yildiz, H., Pothen, L., Yombi, J. C., Dewulf, J., Scohy, A., Gerard, L.,
1235 Wittebole, X., Laterre, P. F., Miller, S. E., Devuyst, O., Jadoul, M., Morelle, J. &
1236 Cliniques universitaires Saint-Luc, C.-R. G. SARS-CoV-2 causes a specific
1237 dysfunction of the kidney proximal tubule. *Kidney Int* **98**, 1296-1307,
1238 doi:10.1016/j.kint.2020.07.019 (2020).
- 1239 102 Hanley, B., Naresh, K. N., Roufosse, C., Nicholson, A. G., Weir, J., Cooke, G. S.,
1240 Thursz, M., Manousou, P., Corbett, R., Goldin, R., Al-Sarraj, S., Abdolrasouli, A.,
1241 Swann, O. C., Baillon, L., Penn, R., Barclay, W. S., Viola, P. & Osborn, M.
1242 Histopathological findings and viral tropism in UK patients with severe fatal COVID-
1243 19: a post-mortem study. *Lancet Microbe* **1**, e245-e253, doi:10.1016/S2666-
1244 5247(20)30115-4 (2020).
- 1245 103 Amraei, R., Yin, W., Napoleon, M. A., Suder, E. L., Berrigan, J., Zhao, Q., Olejnik, J.,
1246 Chandler, K. B., Xia, C., Feldman, J., Hauser, B. M., Caradonna, T. M., Schmidt, A.
1247 G., Gummuluru, S., Muhlberger, E., Chitalia, V., Costello, C. E. & Rahimi, N.
1248 CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2. *bioRxiv*,
1249 doi:10.1101/2020.06.22.165803 (2021).
- 1250 104 Singh, M., Bansal, V. & Feschotte, C. A Single-Cell RNA Expression Map of Human
1251 Coronavirus Entry Factors. *Cell reports* **32**, 108175, doi:10.1016/j.celrep.2020.108175
1252 (2020).
- 1253 105 Kuppe, C., Leuchte, K., Wagner, A., Kabgani, N., Saritas, T., Puelles, V. G., Smeets,
1254 B., Hakrrouch, S., van der Vlag, J., Boor, P., Schiffer, M., Grone, H. J., Fogo, A., Floege,
1255 J. & Moeller, M. J. Novel parietal epithelial cell subpopulations contribute to focal
1256 segmental glomerulosclerosis and glomerular tip lesions. *Kidney Int* **96**, 80-93,
1257 doi:10.1016/j.kint.2019.01.037 (2019).
- 1258 106 Wang, M. Not your usual parietal cell. *Nature reviews. Nephrology* **15**, 318,
1259 doi:10.1038/s41581-019-0141-8 (2019).
- 1260 107 Broer, S., Bailey, C. G., Kowalczyk, S., Ng, C., Vanslambrouck, J. M., Rodgers, H.,
1261 Auray-Blais, C., Cavanaugh, J. A., Broer, A. & Rasko, J. E. Iminoglycinuria and

- 1262 hyperglycinuria are discrete human phenotypes resulting from complex mutations in
1263 proline and glycine transporters. *J Clin Invest* **118**, 3881-3892, doi:10.1172/JCI36625
1264 36625 [pii] (2008).
- 1265 108 van Dijk, D., Sharma, R., Nainys, J., Yim, K., Kathail, P., Carr, A. J., Burdziak, C.,
1266 Moon, K. R., Chaffer, C. L., Pattabiraman, D., Bierie, B., Mazutis, L., Wolf, G.,
1267 Krishnaswamy, S. & Pe'er, D. Recovering Gene Interactions from Single-Cell Data
1268 Using Data Diffusion. *Cell* **174**, 716-729 e727, doi:10.1016/j.cell.2018.05.061 (2018).
- 1269 109 Boyle, S. C., Kim, M., Valerius, M. T., McMahon, A. P. & Kopan, R. Notch pathway
1270 activation can replace the requirement for Wnt4 and Wnt9b in mesenchymal-to-
1271 epithelial transition of nephron stem cells. *Development* **138**, 4245-4254,
1272 doi:10.1242/dev.070433 (2011).
- 1273 110 Chung, E., Deacon, P. & Park, J. S. Notch is required for the formation of all nephron
1274 segments and primes nephron progenitors for differentiation. *Development* **144**, 4530-
1275 4539, doi:10.1242/dev.156661 (2017).
- 1276 111 Surendran, K., Boyle, S., Barak, H., Kim, M., Stomberski, C., McCright, B. & Kopan,
1277 R. The contribution of Notch1 to nephron segmentation in the developing kidney is
1278 revealed in a sensitized Notch2 background and can be augmented by reducing Mint
1279 dosage. *Dev Biol* **337**, 386-395, doi:10.1016/j.ydbio.2009.11.017 (2010).
- 1280 112 Karner, C. M., Das, A., Ma, Z., Self, M., Chen, C., Lum, L., Oliver, G. & Carroll, T. J.
1281 Canonical Wnt9b signaling balances progenitor cell expansion and differentiation
1282 during kidney development. *Development* **138**, 1247-1257, doi:10.1242/dev.057646
1283 (2011).
- 1284 113 Park, J. S., Valerius, M. T. & McMahon, A. P. Wnt/beta-catenin signaling regulates
1285 nephron induction during mouse kidney development. *Development* **134**, 2533-2539,
1286 doi:10.1242/dev.006155 (2007).
- 1287 114 Blank, U., Brown, A., Adams, D. C., Karolak, M. J. & Oxburgh, L. BMP7 promotes
1288 proliferation of nephron progenitor cells via a JNK-dependent mechanism.
1289 *Development* **136**, 3557-3566, doi:10.1242/dev.036335 (2009).

- 1290 115 Lindstrom, N. O., Carragher, N. O. & Hohenstein, P. The PI3K pathway balances self-
1291 renewal and differentiation of nephron progenitor cells through beta-catenin signaling.
1292 *Stem Cell Reports* **4**, 551-560, doi:10.1016/j.stemcr.2015.01.021 (2015).
- 1293 116 Muthukrishnan, S. D., Yang, X., Friesel, R. & Oxburgh, L. Concurrent BMP7 and
1294 FGF9 signalling governs AP-1 function to promote self-renewal of nephron progenitor
1295 cells. *Nature communications* **6**, 10027, doi:10.1038/ncomms10027 (2015).
- 1296 117 Tanigawa, S., Naganuma, H., Kaku, Y., Era, T., Sakuma, T., Yamamoto, T., Taguchi,
1297 A. & Nishinakamura, R. Activin Is Superior to BMP7 for Efficient Maintenance of
1298 Human iPSC-Derived Nephron Progenitors. *Stem Cell Reports* **13**, 322-337,
1299 doi:10.1016/j.stemcr.2019.07.003 (2019).
- 1300 118 Lindstrom, N. O., Hohenstein, P. & Davies, J. A. Nephrons require Rho-kinase for
1301 proximal-distal polarity development. *Sci Rep* **3**, 2692, doi:10.1038/srep02692 (2013).
- 1302 119 Barasch, J., Yang, J., Ware, C. B., Taga, T., Yoshida, K., Erdjument-Bromage, H.,
1303 Tempst, P., Parravicini, E., Malach, S., Aranoff, T. & Oliver, J. A. Mesenchymal to
1304 epithelial conversion in rat metanephros is induced by LIF. *Cell* **99**, 377-386 (1999).
- 1305 120 Bard, J. B. & Ross, A. S. LIF, the ES-cell inhibition factor, reversibly blocks
1306 nephrogenesis in cultured mouse kidney rudiments. *Development* **113**, 193-198 (1991).
- 1307 121 Matsuda, M., Hayashi, H., Garcia-Ojalvo, J., Yoshioka-Kobayashi, K., Kageyama, R.,
1308 Yamanaka, Y., Ikeya, M., Toguchida, J., Alev, C. & Ebisuya, M. Species-specific
1309 segmentation clock periods are due to differential biochemical reaction speeds. *Science*
1310 **369**, 1450-1455, doi:10.1126/science.aba7668 (2020).
- 1311 122 Lancaster, M. A., Renner, M., Martin, C. A., Wenzel, D., Bicknell, L. S., Hurles, M.
1312 E., Homfray, T., Penninger, J. M., Jackson, A. P. & Knoblich, J. A. Cerebral organoids
1313 model human brain development and microcephaly. *Nature* **501**, 373-379,
1314 doi:10.1038/nature12517 (2013).
- 1315 123 Velasco, S., Kedaigle, A. J., Simmons, S. K., Nash, A., Rocha, M., Quadrato, G.,
1316 Paulsen, B., Nguyen, L., Adiconis, X., Regev, A., Levin, J. Z. & Arlotta, P. Individual
1317 brain organoids reproducibly form cell diversity of the human cerebral cortex. *Nature*
1318 **570**, 523-527, doi:10.1038/s41586-019-1289-x (2019).

- 1319 124 Bantounas, I., Silajdzic, E., Woolf, A. S. & Kimber, S. J. Formation of Mature
1320 Nephrons by Implantation of Human Pluripotent Stem Cell-Derived Progenitors into
1321 Mice. *Methods in molecular biology* **2067**, 309-322, doi:10.1007/978-1-4939-9841-
1322 8_19 (2020).
- 1323 125 Nam, S. A., Seo, E., Kim, J. W., Kim, H. W., Kim, H. L., Kim, K., Kim, T. M., Ju, J.
1324 H., Gomez, I. G., Uchimura, K., Humphreys, B. D., Yang, C. W., Lee, J. Y., Kim, J.,
1325 Cho, D. W., Freedman, B. S. & Kim, Y. K. Graft immaturity and safety concerns in
1326 transplanted human kidney organoids. *Exp Mol Med* **51**, 1-13, doi:10.1038/s12276-
1327 019-0336-x (2019).
- 1328 126 van den Berg, C. W., Ritsma, L., Avramut, M. C., Wiersma, L. E., van den Berg, B.
1329 M., Leuning, D. G., Lievers, E., Koning, M., Vanslambrouck, J. M., Koster, A. J.,
1330 Howden, S. E., Takasato, M., Little, M. H. & Rabelink, T. J. Renal Subcapsular
1331 Transplantation of PSC-Derived Kidney Organoids Induces Neo-vasculogenesis and
1332 Significant Glomerular and Tubular Maturation In Vivo. *Stem Cell Reports* **10**, 751-
1333 765, doi:10.1016/j.stemcr.2018.01.041 (2018).
- 1334 127 Silhol, F., Sarlon, G., Deharo, J. C. & Vaisse, B. Downregulation of ACE2 induces
1335 overstimulation of the renin-angiotensin system in COVID-19: should we block the
1336 renin-angiotensin system? *Hypertens Res* **43**, 854-856, doi:10.1038/s41440-020-0476-
1337 3 (2020).
- 1338 128 Reddy, R., Asante, I., Liu, S., Parikh, P., Liebler, J., Borok, Z., Rodgers, K., Baydur,
1339 A. & Louie, S. G. Circulating angiotensin peptides levels in Acute Respiratory Distress
1340 Syndrome correlate with clinical outcomes: A pilot study. *PLoS One* **14**, e0213096,
1341 doi:10.1371/journal.pone.0213096 (2019).
- 1342 129 Diaz, J. H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin
1343 receptor blockers may increase the risk of severe COVID-19. *J Travel Med* **27**,
1344 doi:10.1093/jtm/taaa041 (2020).
- 1345 130 Esler, M. & Esler, D. Can angiotensin receptor-blocking drugs perhaps be harmful in
1346 the COVID-19 pandemic? *J Hypertens* **38**, 781-782,
1347 doi:10.1097/HJH.0000000000002450 (2020).

- 1348 131 Fang, L., Karakiulakis, G. & Roth, M. Are patients with hypertension and diabetes
1349 mellitus at increased risk for COVID-19 infection? *Lancet Respir Med* **8**, e21,
1350 doi:10.1016/S2213-2600(20)30116-8 (2020).
- 1351 132 Hippisley-Cox, J., Young, D., Coupland, C., Channon, K. M., Tan, P. S., Harrison, D.
1352 A., Rowan, K., Aveyard, P., Pavord, I. D. & Watkinson, P. J. Risk of severe COVID-
1353 19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study
1354 including 8.3 million people. *Heart* **106**, 1503-1511, doi:10.1136/heartjnl-2020-
1355 317393 (2020).
- 1356 133 Li, M., Wang, Y., Ndiwane, N., Orner, M. B., Palacios, N., Mittler, B., Berlowitz, D.,
1357 Kazis, L. E. & Xia, W. The association of COVID-19 occurrence and severity with the
1358 use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in
1359 patients with hypertension. *PLoS One* **16**, e0248652,
1360 doi:10.1371/journal.pone.0248652 (2021).
- 1361 134 Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A. &
1362 Solomon, S. D. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with
1363 Covid-19. *N Engl J Med* **382**, 1653-1659, doi:10.1056/NEJMsr2005760 (2020).
- 1364 135 Herrera, S., Bernal-Maurandi, J., Cofan, F., Ventura, P., Marcos, M. A., Linares, L.,
1365 Cuesta, G., Diekmann, F., Moreno, A. & Bodro, M. BK Virus and Cytomegalovirus
1366 Coinfections in Kidney Transplantation and Their Impact on Allograft Loss. *J Clin Med*
1367 **10**, doi:10.3390/jcm10173779 (2021).
- 1368 136 Schutgens, F., Rookmaaker, M. B., Margaritis, T., Rios, A., Ammerlaan, C., Jansen, J.,
1369 Gijzen, L., Vormann, M., Vonk, A., Viveen, M., Yengej, F. Y., Derakhshan, S., de
1370 Winter-de Groot, K. M., Artegiani, B., van Boxtel, R., Cuppen, E., Hendrickx, A. P.
1371 A., van den Heuvel-Eibrink, M. M., Heitzer, E., Lanz, H., Beekman, J., Murk, J. L.,
1372 Masereeuw, R., Holstege, F., Drost, J., Verhaar, M. C. & Clevers, H. Tubuloids derived
1373 from human adult kidney and urine for personalized disease modeling. *Nature*
1374 *biotechnology* **37**, 303-313, doi:10.1038/s41587-019-0048-8 (2019).
- 1375 137 Briggs, J. A., Sun, J., Shepherd, J., Ovchinnikov, D. A., Chung, T. L., Nayler, S. P.,
1376 Kao, L. P., Morrow, C. A., Thakar, N. Y., Soo, S. Y., Peura, T., Grimmond, S. &
1377 Wolvetang, E. J. Integration-free induced pluripotent stem cells model genetic and


- 1378 neural developmental features of down syndrome etiology. *Stem Cells* **31**, 467-478,
1379 doi:10.1002/stem.1297 (2013).
- 1380 138 Vlahos, K., Sourris, K., Mayberry, R., McDonald, P., Bruveris, F. F., Schiesser, J. V.,
1381 Bozaoglu, K., Lockhart, P. J., Stanley, E. G. & Elefanty, A. G. Generation of iPSC lines
1382 from peripheral blood mononuclear cells from 5 healthy adults. *Stem Cell Res* **34**,
1383 101380, doi:10.1016/j.scr.2018.101380 (2019).
- 1384 139 Chen, G., Gulbranson, D. R., Hou, Z., Bolin, J. M., Ruotti, V., Probasco, M. D., Smuga-
1385 Otto, K., Howden, S. E., Diol, N. R., Propson, N. E., Wagner, R., Lee, G. O.,
1386 Antosiewicz-Bourget, J., Teng, J. M. & Thomson, J. A. Chemically defined conditions
1387 for human iPSC derivation and culture. *Nat Methods* **8**, 424-429,
1388 doi:10.1038/nmeth.1593 (2011).
- 1389 140 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T.,
1390 Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J. Y., White, D. J.,
1391 Hartenstein, V., Eliceiri, K., Tomancak, P. & Cardona, A. Fiji: an open-source platform
1392 for biological-image analysis. *Nat Methods* **9**, 676-682, doi:10.1038/nmeth.2019
1393 (2012).
- 1394 141 Stoeckius, M., Zheng, S., Houck-Loomis, B., Hao, S., Yeung, B. Z., Mauck, W. M.,
1395 3rd, Smibert, P. & Satija, R. Cell Hashing with barcoded antibodies enables
1396 multiplexing and doublet detection for single cell genomics. *Genome Biol* **19**, 224,
1397 doi:10.1186/s13059-018-1603-1 (2018).
- 1398 142 Ransick, A., Lindstrom, N. O., Liu, J., Zhu, Q., Guo, J. J., Alvarado, G. F., Kim, A. D.,
1399 Black, H. G., Kim, J. & McMahon, A. P. Single-Cell Profiling Reveals Sex, Lineage,
1400 and Regional Diversity in the Mouse Kidney. *Developmental cell* **51**, 399-413 e397,
1401 doi:10.1016/j.devcel.2019.10.005 (2019).
- 1402 143 Hafemeister, C. & Satija, R. Normalization and variance stabilization of single-cell
1403 RNA-seq data using regularized negative binomial regression. *Genome Biol* **20**, 296,
1404 doi:10.1186/s13059-019-1874-1 (2019).
- 1405 144 Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell
1406 transcriptomic data across different conditions, technologies, and species. *Nature*
1407 *biotechnology* **36**, 411-420, doi:10.1038/nbt.4096 (2018).

1408 145 Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., 3rd,
1409 Hao, Y., Stoeckius, M., Smibert, P. & Satija, R. Comprehensive Integration of Single-
1410 Cell Data. *Cell* **177**, 1888-1902 e1821, doi:10.1016/j.cell.2019.05.031 (2019).

1411

1412


1413 **Figures and legends**



1414

1415 **Figure 1: Extended monolayer culture in CDBLY supports nephron progenitors and**
 1416 **preserves nephrogenic capacity. A.** Schematic depicting the extended differentiation protocol
 1417 in CDBLY2. **B.** Brightfield and confocal immunofluorescence images of extended monolayer
 1418 differentiations in E6, CDBLY and NPSR, and resulting organoids. Immunofluorescence
 1419 depicts nephrons (EPCAM; green), podocytes of glomeruli (NPHS1; grey), and proximal
 1420 tubules (LTL; blue). Scale bars represent 100µm (monolayers) and 200µm (organoids). **C.**
 1421 Brightfield images of extended monolayer differentiations using CDBLY variations and
 1422 resulting organoids. Scale bars represent 100µm (monolayers) and 200µm (organoids). **D.**
 1423 qRT-PCR analysis of standard and extended monolayer differentiations. Error bars represent
 1424 SEM from n = 3 biological replicates. Statistical significance was determined using an unpaired
 1425 t test. Asterisks represent P values adjusted for multiple comparisons using the Holm-Sidak
 1426 method, alpha = 0.05 (*; P ≤ 0.05, **; P ≤ 0.01, ***; P ≤ 0.001, ****; P ≤ 0.0001).

1427



1428

1429 **Figure 2: Extended monolayer culture in CDBLY2 increases SIX2⁺ progenitor**

1430 **contribution to nephrons and proximalisation. A.** Confocal immunofluorescence of D14 +

1431 7 organoid derived from the SIX2^{Cre} lineage tracing iPSC line. Images depict merged and

1432 separated channels showing lineage-traced SIX2⁺ cells (mCherry; red), distal tubules (ECAD;

1433 green), podocytes (NPHS1; grey) and proximal tubules (LTL; blue). Scale bar represents 100

1434 μ m. **B.** Flow cytometry of SIX2^{Cre/Cre}:GAPDH^{dual} lineage tracing organoids derived from


1435 extended (13 day + CDBLY2) and standard (7 day + E6 media) differentiations depicting

1436 mCherry contribution to the EPCAM⁺ (nephron) population. Flow plots shown in (i) are

1437 representative of the replicates across multiple experiments. Percentage mCherry contributions

1438 from flow cytometry are depicted in bar graph (ii). Error bars in (ii) represent SEM from n =
1439 4 biological replicates across 3 independent experiments. Statistical significance was
1440 determined using an unpaired t test. Asterisks represent P values adjusted for multiple
1441 comparisons using the Holm-Sidak method, alpha = 0.05 (*; $P \leq 0.05$, **; $P \leq 0.01$, ***; $P \leq$
1442 0.001, ****; $P \leq 0.0001$). **C.** Confocal immunofluorescence of a D13+14 organoid
1443 demonstrating aligned nephron morphology as well as nephron segmentation makers; nephron
1444 epithelium (EpCAM; green), distal tubule/Loop of Henle (SLC12A1; red), proximal tubules
1445 (LTL; blue), and podocytes (NPHS1; grey). Scale bar represents 200 μm . **C.** Confocal
1446 immunofluorescence of a D13+14 organoid demonstrating few GATA3⁺ (connecting
1447 segment/ureteric epithelium; red) cells, co-stained for nephron epithelium (EPCAM; green),
1448 podocytes (NPHS1; grey), and proximal tubules (LTL; blue). Inset shows GATA3 and LTL
1449 alone. Scale bar represents 100 μm . **D.** Flow cytometry of representative HNF4A^{YFP} derived
1450 organoids generated using the extended differentiation + CDBLY2 protocol (generating PT-
1451 enhanced organoids) or the standard organoid protocol.

1452




1453

1454 **Figure 3: Single cell transcriptional profiling (scRNAseq) shows improved specification,**
 1455 **patterning and maturation of proximal tubules and their progenitors. A. Schematic**

1456 depicting experimental design and profiled samples. Multiple organoids (2.5×10^5 cells per
1457 organoid) were generated from each of the 4 replicate differentiated cell monolayers at D13.
1458 The remaining portion of cells from each replicate monolayer were barcoded and pooled for
1459 generation of the D13 monolayer library. The resulting organoids were cultured for 14 days
1460 before being harvested and pooled within replicate wells, making 4 cell suspensions. These 4
1461 suspensions were individually barcoded and pooled into a single cell suspension for generation
1462 of the D13+14 organoid library. **B.** UMAP plots of D13 and D13+14 samples (pooled
1463 replicates) identifying 16 and 17 distinct cell clusters, respectively. **C.** *ComparePlots* depicting
1464 proportions of kidney cell types (nephron-specific populations only) in D13 and D13+14
1465 sample replicates as classified by *DevKidCC*. Population abbreviations: nephron progenitor
1466 cell (NPC), early nephron (EN), early distal tubule (EDT), DT (distal tubule), loop of Henle
1467 (LOH), early proximal tubule (EPT), proximal tubule (PT), parietal epithelial cell (PEC), early
1468 podocyte (EPod), podocyte (Pod). **D.** *DevKidCC* dot plots comparing the expression of gene
1469 signatures for (i) self-renewing (*SIX1*, *SIX2*, *CITED1*, *WASF3*, *DAPL1*, *MEOX1*, *TMEM100*,
1470 *ROBO2*, *CRABP2*), committed (*SIX1*, *SIX2*, *LYPD1*), and primed (*DAPL1*, *NOTCH2*, *MEG3*)
1471 NPC subsets, as well as (ii) metanephric HOX genes, within the D13 monolayer NPC
1472 population to that of published stem cell-derived kidney datasets and a mixed (week 11 – 18)
1473 human fetal kidney reference dataset (Hochane, *et al.*, 2019; Tran, *et al.*, 2019; Hollywood, *et*
1474 *al.*, 2020). Comparisons were made to published monolayer and early nephrogenic datasets
1475 (Subramanian, *et al.*, 2019; Wu, *et al.*, 2018; Low, *et al.*, 2019; Tran, *et al.*, 2019) as outlined
1476 previously (Wilson, *et al.*, 2021). **E.** *DevKidCC* dot plot comparing the expression of proximal
1477 nephron (PN) gene signatures within the EPT population of D13+14 organoids to that of
1478 published stem cell-derived kidney organoid datasets (Czerniecki, *et al.*, 2018; Harder, *et al.*,
1479 2019; Kumar, *et al.*, 2019) and the mixed week 11 - 18 fetal kidney reference dataset (Hochane,
1480 *et al.*, 2019; Tran, *et al.*, 2019; Hollywood, *et al.*, 2020) as outlined previously (Wilson, *et al.*,
1481 2021). **F.** Violin plots in (i) and (ii) compare PT-specific gene expression between line- and
1482 age-matched standard (blue) and PT-enhanced (red) organoids. Genes encoding auxiliary
1483 proteins around outlined (bottom row). Violin plots for *SLC22A2* and *SLC22A6* are redisplayed
1484 as dot plots in (ii). **G.** Violin plots comparing examples of genes involved in fatty acid
1485 metabolism in line- and age-matched standard (blue) and PT-enhanced (red) organoids.

1486



1487


1488 **Figure 4: PT-enhanced organoids express mature and functional PT transporters and**

1489 **transcription factors at a protein level. A.** Confocal immunofluorescence of PT markers

1490 within EPCAM+ (green) nephrons in D13+14 PT-enhanced kidney, including (Ai) LTL (blue),

1491 CUBILIN (CUBN; grey), MEGALIN (MEG; red), (Aii) SLC6A19 (green), and (Aiii) HNF4A

1492 (red). Podocytes (Aiii) are marked by NPHS1 (grey). Scale bars in (Ai) and (Aiii) represent
1493 200 μ m. Scale bar in (Aii) represents 100 μ m. **Bi.** Confocal images of live organoids under
1494 phase-contrast depicting uptake of TRITC-albumin (red) into MEGALIN-positive PTs (blue).
1495 Outlined area of whole organoid image (left) is shown at higher magnification on right panel.
1496 Inset (right panel) depicts MEGALIN (blue) staining alone. Scale bars represent 200 μ m (left)
1497 and 100 μ m (right). **Bii.** Confocal images of live organoids under phase-contrast depicting
1498 DAPI uptake as a surrogate for organic cation transport capacity. Left and right panels show
1499 organoids exposed to substrate (DAPI; blue) alone and to a combination of substrate and
1500 inhibitor (Cimetidine), respectively. Dead cells in both panels are labelled with DRAQ7 (red).
1501 Scale bars represent 100 μ m. **C.** Confocal immunofluorescence of representative D13+14
1502 organoids following 24 hours treatment with E6 media containing either 20 μ M cisplatin (Cii)
1503 or an equivalent volume of PBS (Ci). Images depict KIM-1-expressing cells (red) in LTL+
1504 proximal tubules (blue) with nephron epithelium marked by EPCAM (green). Insets show red
1505 channel (KIM-1) alone. Scale bars represent 100 μ m. **D.** qRT-PCR analysis of D13+14 control
1506 and cisplatin-treated organoids from (C). Error bars represent SEM from n = 8 (control) and n
1507 = 9 (cisplatin treated) biological replicates across 3 independent experiments. Statistical
1508 significance was determined using an unpaired t test. Asterisk represents P value (**; $P \leq 0.01$)
1509 adjusted for multiple comparisons using the Holm-Sidak method, alpha = 0.05.



1510


1511 **Figure 5. WNT signalling gradient influences nephron alignment and directionality. A.**

1512 Brightfield and confocal immunofluorescence images of organoids derived from 13 days of
1513 extended monolayer culture in CDBLY2, with varying initial CHIR exposure conditions during
1514 first 7 days. Bottom panels depict nephron segmentation markers; nephron epithelium
1515 (EPCAM; green), ureteric epithelium/connecting segment (GATA3; red), proximal tubules
1516 (LTL; blue), and podocytes (NPHS1; grey). Scale bar represents 200 µm. **B.** Representative
1517 brightfield image (top) of a day 13+15 organoid exposed to 5 days x 6µM CHIR prior to
1518 CDBLY2 addition at monolayer differentiation day 8. White box indicates approximate regions
1519 of cross sections shown in bottom panels stained with Alcian blue to indicate cartilage
1520 formation in central core region (blue). Scale bars represent 200 µm. **C.** Confocal
1521 immunofluorescence images of replicate standard organoids bioprinted in a patch conformation

1522 and in contact with either agarose beads soaked PBS (control; Di) or in 10 μ M IWR-1 (Dii).
1523 Clusters of beads are outlined with red dashed lines. Organoids are stained with markers of
1524 epithelium (EPCAM; green), proximal tubule (LTL; blue), and podocytes of the glomeruli
1525 (NPHS1; grey). Scale bars represent 100 μ m (all top panels) and 200 μ m (bottom tile panels).

1526

1527




1528

1529 **Figure 6: PT-enhanced organoids show improved SARS-CoV-2 entry factor expression.**

1530 **A.** scRNASeq analysis of SARS-CoV-2 entry factor expression in D13+14 kidney organoids.
1531 Boxes outline proximal (red), distal (blue), and endothelial (green) clusters. **B.** scRNASeq
1532 analysis of SARS-CoV-2 entry factor expression in age- and line- matched standard (blue) and
1533 PT-enhanced (red) (D13+12) kidney organoids. Feature plots and violin plots compare
1534 expression of genes within integrated datasets from which distal tubule (DT; Bi) and proximal
1535 tubule (PT; Bii) clusters have been isolated. **C.** Confocal immunofluorescence of ACE2 (green)
1536 and TMPRSS2 (red) demonstrating protein localisation in PT-enhanced kidney organoids.
1537 Nephron epithelium is stained with EPCAM (green). Entry factors, ACE2 and TMPRSS2, are
1538 depicted in grey and red, while arrow indicates a section of continuous nephron epithelium
1539 with distinctly separate ACE2 and TMPRSS2 expression. Scale bars represent 50µm.

1540

1541



1542

1543 **Figure 7: PT-enhanced organoids show evidence of SARS-CoV-2 infection and improved**

1544 **viral replication. A.** Virus titre expressed as median Tissue Culture Infectious Dose (TCID₅₀)

1545 of SARS-CoV-2-infected (red bars) and mock-infected (grey bars) PT-enhanced organoids.

1546 Dotted line represents lower limit of detection (LOD). Error bars represent SEM from n = 3

1547 independent experiments infecting 2 – 4 wells per experiment (3 organoids per well) .

1548 Statistical significance was determined using an unpaired t test. Asterisk represents P value

1549 adjusted for multiple comparisons using the Holm-Sidak method, alpha = 0.05 (*; P ≤ 0.05, **;

1550 P ≤ 0.01, ***; P ≤ 0.001, ****; P ≤ 0.0001).

1551 **B.** Virus titre in SARS-CoV-2-infected standard

1552 organoids (blue bars) and PT-enhanced organoids (red bars). Dotted line represents lower limit

1553 of detection (LOD). Error bars represent SEM from n = 3 wells (3 organoids per well) across

1554 independent experiments replicated using the same iPSC line and organoid conditions.

1555 Statistical significance was determined using a two-way ANOVA with Geisser-Greenhouse

1556 correction and uncorrected Fisher's LSD (individual variances computed for each comparison).

1557 Asterisks represent P values (*; P ≤ 0.05, **; P ≤ 0.01, ***; P ≤ 0.001, ****; P ≤ 0.0001).

1558 **C.** Confocal immunofluorescence of PT-enhanced organoids 6 days post-infection indicating viral

1559 dsRNA (red) localisation, co-stained for PTs (LTL; blue), Loop of Henle (SLC12A1; apical

1560 green), and podocytes (NPHS1; grey). Scale bars represent 50µm.

1560

1561